Author: "E. Grapsa" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"E. Grapsa"' showing total 101 results

Start Over Author "E. Grapsa"

101 results on '"E. Grapsa"'

1. Generation of a novel decay accelerating factor (DAF) knock-out rat model using clustered regularly-interspaced short palindromic repeats, (CRISPR)/associated protein 9 (Cas9), genome editing

Author: Maria G, Detsika, K, Goudevenou, A M, Geurts, H, Gakiopoulou, E, Grapsa, and Elias A, Lianos
Subjects: CD55 Antigens, Podocytes, Heymann Nephritis Antigenic Complex, Complement C5, Complement C3-C5 Convertases, Acute Kidney Injury, Antibodies, Anti-Idiotypic, Rats, Gene Knockout Techniques, Albuminuria, Animals, Humans, CRISPR-Cas Systems, Complement Activation
Abstract: Decay accelerating factor (DAF), a key complement activation control protein, is a 70 kDa membrane bound glycoprotein which controls extent of formation of the C3 and C5 convertases by accelerating their decay. Using clustered regularly-interspaced short palindromic repeats, (CRISPR)/associated protein 9 (Cas9) genome editing we generated a novel DAF deficient (Daf
Published: 2020

2. Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology

Author: Čelutkienė, J. Lainscak, M. Anderson, L. Gayat, E. Grapsa, J. Harjola, V.-P. Manka, R. Nihoyannopoulos, P. Filardi, P.P. Vrettou, R. Anker, S.D. Filippatos, G. Mebazaa, A. Metra, M. Piepoli, M. Ruschitzka, F. Zamorano, J.L. Rosano, G. Seferovic, P.
Abstract: Acute heart failure is one of the main diagnostic and therapeutic challenges in clinical practice due to a non-specific clinical manifestation and the urgent need for timely and tailored management at the same time. In this position statement, the Heart Failure Association aims to systematize the use of various imaging methods in accordance with the timeline of acute heart failure care proposed in the recent guidelines of the European Society of Cardiology. During the first hours of admission the point-of-care focused cardiac and lung ultrasound examination is an invaluable tool for rapid differential diagnosis of acute dyspnoea, which is highly feasible and relatively easy to learn. Several portable and stationary imaging modalities are being increasingly used for the evaluation of cardiac structure and function, haemodynamic and volume status, precipitating myocardial ischaemia or valvular abnormalities, and systemic and pulmonary congestion. This paper emphasizes the central role of the full echocardiographic examination in the identification of heart failure aetiology, severity of cardiac dysfunction, indications for specific heart failure therapy, and risk stratification. Correct evaluation of cardiac filling pressures and accurate prognostication may help to prevent unscheduled short-term readmission. Alternative advanced imaging modalities should be considered to assist patient management in the pre- and post-discharge phase, including cardiac magnetic resonance, computed tomography, nuclear studies, and coronary angiography. The Heart Failure Association addresses this paper to the wide spectrum of acute care and heart failure specialists, highlighting the value of all available imaging techniques at specific stages and in common clinical scenarios of acute heart failure. © 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiology
Published: 2020

3. Training patients with chronic kidney disease for proper oral hygiene

Author: T, Vassilikopoulos, primary, A, Petropoulou, additional, and E, Grapsa, additional
Published: 2020
Full Text: View/download PDF

4. Demographic scenarios for the EU : migration, population and education

Author: D. Ghio, Raya Muttarak, A. Conte, G. Amran, Alain Bélanger, K. Jensen, Marcin Stonawski, Michaela Potančoková, E. Grapsa, Elke Loichinger, Patrick Sabourin, N. Gailey, and Guillaume Marois
Subjects: Frontier, education.field_of_study, Population ageing, Political science, Development economics, Population, Population growth, East Asia, Resizing, education, Futures contract, Emigration
Abstract: Over the recent decades, the EU has been shaped by population growth, but now its population is ageing. Together with North America and East Asia, the EU is moving towards longer-living, lower-fertility, and higher-educated societies. Facing this new demographic frontier naturally prompts the questions: Who will live and work in Europe in the coming decades? How many, and with what skills? To answer these, this report examines the key factors that will shape European demographics over the coming decades. By examining not only the role of migration, fertility and mortality, but also education levels and labour force participation rates, a more comprehensive view of possible futures can be outlined than the conventional demographic projections allow for. The first five sections of this report focus on demographic challenges inside the EU, such as population ageing, a shrinking labour force, more non-working people being dependent on working people, and showing the impact of high levels of emigration in some EU Member States. With these challenges in mind and with a view towards 2060, the report builds scenarios to understand the long-term effects of changes in key trends, and whether undesirable consequences can be limited or counteracted. As the EU and its demographics do not exist in isolation, the following sections explore the relevant trends for world demographics and for migration flows.
Published: 2019

5. HAEMODIALYSIS TECHNIQUES AND ADEQUACY 2

Author: P. Chamney, U. Moissl, P. Wabel, C. Amato, S. Stuard, M. Menzer, C. Vollmeier, G. Williams, R. Shrivastava, J. Chess, E. Catling, C. Brown, E. Baker, R. Ashcroft, A. Mikhail, L. Djukanovic, Z. Djuric, V. Knezevic, T. Lazarevic, S. Ljubenovic, R. Markovic, V. Rabrenovic, J. Marinkovic, N. Dimkovic, L. Lebourg, C. Ridel, H. De Preneuf, F. Le Roy, T. Petitclerc, M. Wester, F. Simonis, J. P. Kooman, W. H. Boer, K. G. F. Gerritsen, J. A. Joles, K.-i. Yamamoto, K. Eguchi, S. Hirakawa, J. Murakami, T. Akiba, M. Mineshima, D. Stamopoulos, N. Mpakirtzi, A. Lavranos, M. Panagiotou, D. Barbarousi, C. Matsouka, E. Grapsa, S. R. Abbas, F. Zhu, G. A. Kaysen, P. Kotanko, N. W. Levin, A. Vasilevsky, G. Konoplev, O. Stepanova, A. Rubinsky, A. Zemchenkov, R. Gerasimchuk, A. Frorip, T. Abe, K.-I. Yamamoto, I. Ishimori, M. Kusztal, T. Go Biowski, K. Letachowicz, P. Koni Ski, G. Witkowski, P. Pozna Ski, W. Weyde, M. Klinger, M. Ito, S. Ito, M. Suzuki, I. Masakane, D. Navarro, C. Goncalves, A. C. Ferreira, C. Jorge, C. Gil, I. Aires, P. Matias, M. Mendes, A. Azevedo, F. Gomes, A. Ferreira, C. Perazzini, L. Scutiero, L. Brighenti, A. Surace, D. Steckiph, P. Rovatti, S. Severi, J. Soltysiak, A. Warzywoda, A. Musielak, D. Ostalska-Nowicka, J. Zachwieja, T. Goeksel, H. Garnier, M. Ritzerfeld, H. Mann, F. Babinet, B. Allard, V. Todorova, C. Hamont, R. Begri, M. Dekker, M. Taks, C. Konings, V. Scharnhorst, J. Borawski, J. Gozdzikiewicz-Lapinska, B. Naumnik, C. A. Lodi, E. Grandi, E. Mancini, A. Santoro, L. Sereni, M. Caiazzo, L. Corazza, M. Atti, G. Palladino, K. Sakurai, T. Saito, H. Hosoya, F. Yamauchi, T. Kurihara, Y. Tanibayashi, N. Ikebe, M. Antonic, J. Gubensek, A. Drozg, E. Vannier, E. Mattio, A. Ragon, P. Brunet, W. Klimm, K. Pleskacz, B. Pietrzak, S. Niemczyk, J. K. Leypoldt, A. Bernardo, M. Muller, T. C. Marbury, B. F. Culleton, A. A. Zeraati, R. Hekmat, H. R. Reyhani, F. Sharifipoor, P. Bolasco, I. Sitzia, A. Monni, M. C. Mereu, A. M. Pinna, F. Logias, T. Ghisu, M. Passaghe, L. Gazzanelli, M. Ganadu, A. Piras, M. Cossu, B. Contu, S. Palleschi, B. Rossi, P. M. Ghezzi, S. Kron, D. Schneditz, T. Leimbach, S. Aign, J. Kron, A. Seker Kockara, M. Kayatas, C. Huzmeli, F. Candan, M. B. Yilmaz, B. A. Ahmed, C. N. Bejosano, S. A. Samra Abouchacra, S. Z. Al Falahi, K. M. Abdul Moniem, H. Dastoor, S. Kim, J. Oh, Y. Sin, J. Kim, and J. Lee
Subjects: 03 medical and health sciences, Transplantation, medicine.medical_specialty, 0302 clinical medicine, Nephrology, business.industry, 030232 urology & nephrology, Medicine, 030204 cardiovascular system & hematology, business, Intensive care medicine
Published: 2014

6. DIALYSIS ANAEMIA

Author: F. Locatelli, G. Choukroun, D. Fliser, J. Moecks, A. Wiggenhauser, A. Gupta, D. W. Swinkels, V. Lin, C. Guss, R. Pratt, P. Carrilho, A. R. Martins, M. Alves, A. Mateus, L. Gusmao, L. Parreira, J. Assuncao, I. Rodrigues, D. Stamopoulos, N. Mpakirtzi, N. Afentakis, E. Grapsa, E. Zitt, G. Sturm, F. Kronenberg, U. Neyer, F. Knoll, K. Lhotta, G. Weiss, B. M. Robinson, M. Larkina, B. Bieber, W. Kleophas, Y. Li, K. McCullough, J. G. Nolen, F. K. Port, R. L. Pisoni, R. M. Kalicki, D. E. Uehlinger, C. Ogawa, F. Kanda, N. Tomosugi, T. Maeda, T. Kuji, T. Fujikawa, M. Shino, K. Shibata, T. Kaneda, M. Nishihara, H. Satta, S.-I. Kawata, N. Koguchi, K. Tamura, N. Hirawa, Y. Toya, S. Umemura, J. Chanliau, H. Martin, K. Stamatelou, L. Gonzalez-Tabares, N. Manamley, M. Farouk, J. Addison, J. Donck, A. Schneider, L. Gutjahr-Lengsfeld, E. Ritz, H. Scharnagl, G. Gelbrich, S. Pilz, I. C. Macdougall, C. Wanner, C. Drechsler, V. Kuntsevich, E. Charen, D. Kobena, N. Sheth, H. Siktel, N. W. Levin, J. F. Winchester, P. Kotanko, G. Kaysen, T. Kuragano, A. Kida, M. Yahiro, M. Nanami, Y. Nagasawa, Y. Hasuike, T. Nakanishi, V. Dimitratou, I. Griveas, E. Lianos, Y. Sasaki, S. Yamazaki, K. Fujita, M. Kurasawa, K. Yorozu, Y. Shimonaka, N. Suzuki, M. Yamamoto, R. Zwiech, J. Szczepa ska, A. Bruzda-Zwiech, A. Rao, J. Gilg, F. Caskey, A. Kirkpantur, M. M. Balci, A. Turkvatan, B. Afsar, M. Alkis, F. Mandiroglu, Y. O. Kim, S. A. Yoon, Y. S. Kim, S. J. Choi, J. W. Min, M. A. Cheong, M. Oue, K. Yamamoto, T. Kimura, W. Fukao, S. Kaibe, P. S. Djuric, J. Ikonomovski, J. Tosic, A. Jankovic, Z. Majster, V. Stankovic Popovic, N. Dimkovic, V. Aicardi Spalloni, L. Del Vecchio, S. Longhi, L. Violo, V. La Milia, G. Pontoriero, I. Macdougall, A. Rumjon, E. Mangahis, L. Goldstein, T. Ryzlewicz, F. Becker, W. Kilgallon, M. Fukasawa, Y. Otake, T. Yamagishi, M. Kamiyama, H. Kobayashi, M. Takeda, T. Toida, Y. Sato, and S. Fujimoto
Subjects: Transplantation, Nephrology
Published: 2014

7. Extracorporeal dialysis: techniques and adequacy - A

Author: D. Steckiph, G. Calabrese, A. Bertucci, A. Mazzotta, G. Vagelli, M. Gonella, D. Stamopoulos, E. Manios, N. Papachristos, E. Grapsa, G. Papageorgiou, V. Gogola, B. So, V. Dey, E. M. Spalding, C. Libetta, P. Esposito, E. Margiotta, P. Maffioli, A. Bonaventura, L. Bianchi, D. Romano, T. Rampino, G. De Rosa, A. Mauric, U. Haug, G. Enzinger, E. Kern-Derstvenscheg, A. Sluga, C. Ausserwinkler, W. Beck, A. R. Rosenkranz, V. Maheshwari, S. Haroon, Y. Loy, L. Samavedham, G. P. Rangaiah, T. Lau, N. Mpakirtzi, M. Panagiotou, D. Barbarousi, C. Matsouka, A. D. Bunani, M. Kowalczyk, P. Bartnicki, M. Banach, J. Rysz, P. Lentini, L. Zanoli, A. Granata, A. Contestabile, A. Basso, G. Berlingo, V. Pellanda, M. de Cal, V. Grazia, A. Clementi, M. Insalaco, R. Dell'Aquila, A. Karkar, M. Abdelrahman, A. R. Martins, L. Parreira, A. S. Duque, I. Rodrigues, A. B. Baffoun, M. A. Youssfi, A. Sayeh, M. Beji, R. Ben Khadra, J. Hmida, M. Akazawa, H. Horiuchi, Y. Hori, A. Yamada, H. Satou, S. Odamaki, S. Nakai, K. Satou, K. Aoki, I. Saito, Y. Kamijo, S. Ogata, Y. Ishibashi, F. Basso, M. Wojewodzka-Zelezniakowicz, D. Cruz, A. Giuliani, L. Blanca Martos, P. Piccinni, C. Ronco, J. Potier, G. Queffeulou, J. Bouet, A. Nilsson, J. Sternby, G. Grundstrom, M. Alquist, M. Ferraresi, M. C. Di Vico, F. N. Vigotti, M. Deagostini, S. Scognamiglio, V. Consiglio, R. Clari, I. Moro, E. Mongilardi, G. B. Piccoli, V. Hancock, S. Huang, K. Nilsson Ekdahl, C. Baldin, M. Petrarulo, D. Mancuso, P. Inguaggiato, G. Canepari, G. Gigliola, C. Ferrando, S. Meinero, C. Sicuso, A. Pacitti, N. Afentakis, T. Tomo, K. Matsuyama, T. Nakata, K. Ishida, T. Takeno, J.-i. Kadota, J. Minakuchi, J. Kastl, M. Merello, C. Boccato, G. Giordana, S. Mazzone, V. Moscardo, B. Reinhardt, R. Knaup, W. Kruger, D. Tovbin, S. Kim, L. Avnon, M. Zlotnik, S. Storch, K. Umimoto, Y. Shimamoto, M. Suyama, M. Miyata, E. Bosch Benitez-Parodi, E. E. Baamonde Laborda, G. Perez, J. I. Ramirez, A. Ramirez Puga, R. Guerra, C. Garcia Canton, M. M. Lago Alonso, A. Toledo, M. D. Checa Andres, F. E. Latif, Y. Mochida, K. Matsumoto, K. Morita, D. Tsutsumi, K. Ishioka, K. Maesato, M. Oka, H. Moriya, S. Hidaka, T. Ohtake, S. Kobayashi, A. Ficheux, N. Gayrard, F. Duranton, C. Guzman, I. Szwarc, J. Bismuth-Mondolfo, P. Brunet, M.-F. Servel, A. Argiles, N. Tsikliras, S. Mademtzoglou, E. Balaskas, M. Zeid, A. Mostafa, M. N. Mowafy, E. I. Abdo, O. M. Al Amin, A. Ksiazek, W. Zaluska, J. Waniewski, M. Debowska, A. Wojcik-Zaluska, M. Elias, H. Francois, E. Obada, H. K. Lorenzo, B. Charpentier, A. Durrbach, S. Beaudreuil, G. Imamovic, D. Marcelli, I. Bayh, R. Hrvacevic, S. Kapun, A. Grassmann, L. Scatizzi, J. Maslovaric, R. Daelemans, S. Mesens, E. A. Mohamed, A. Wafae, H. Kawtar, H. Mohamed Amine, K. Driss, and B. Mohammed
Subjects: Transplantation, medicine.medical_specialty, Extracorporeal Dialysis, Nephrology, business.industry, Medicine, business, Intensive care medicine
Published: 2013

8. Anaemia in CKD 1-5

Author: M. Hirata, Y. Tashiro, K. Aizawa, K. Endo, K. Serizawa, K. Yogo, A. Cases, J. Portoles, J. Calls, A. Martinez-Castelao, M. A. Munar, A. Segarra, E. Samouilidou, K. Pantelias, D. Petras, T. Mpakirtzi, C. Pipili, G. Chatzivasileiou, K. Vasiliou, E. Denda, E. Grapsa, H. Tzanatos, S. Shoji, M. Inaba, N. Tomosugi, S. Okuno, M. Ichii, T. Yamakawa, S. Kurihara, L. Barsan, A. Stanciu, S. Stancu, C. Capusa, L. Bratescu, G. Mircescu, K.-L. Kuo, S.-C. Hung, T.-S. Lee, D.-C. Tarng, I. Nistor, A. Covic, D. Goldsmith, P. Garrido, J. Fernandes, S. Ribeiro, H. Vala, B. Parada, R. Alves, L. Belo, E. Costa, A. Santos-Silva, F. Reis, K. Abdulnabi, A. Ullah, A. Abdulateef, M. Howse, A. Khalil, B. Fouqueray, M. Hoffmann, J. Addison, N. Manamley, D. Stamopoulos, N. Mpakirtzi, N. Afentakis, K.- H. Yu, J. Chou, S. Klaus, M. Schaddelee, M. Kashiwa, A. Takada, T. Neff, J. Galle, K. Claes, S. Di Giulio, A. Guerin, H. Herlitz, I. Kiss, G. Wirnsberger, M. Froissart, C. Winearls, A. Martinez Castelao, A. Cases Amenos, A. Torre Carballada, F. J. Torralba Iranzo, J. M. Bronsoms Artero, D. Toran Monserrat, M. Valles Prats, J. L. Merino, B. Espejo, B. Bueno, Y. Amezquita, V. Paraiso, Z. Kiss, L. Kerkovits, C. Ambrus, I. Kulcsar, J. Szegedi, A. Benke, B. Borbas, S. Ferenczi, M. Hengsperger, S. Kazup, L. Nagy, J. Nemeth, A. Rozinka, T. Szabo, T. Szelestei, E. Toth, G. Varga, G. Wagner, G. Zakar, L. Gergely, K. Exarchou, N. Tanahill, A. Anthoney, S. Ahmed, R. Oprican, M. Lipan, B. Chirculescu, S. Roger, R. Malecki, M. Farouk, F. Dellanna, M. Thomas, M. Touam, F. Chantrel, M. Bouiller, J.-M. Hurot, T. Raphael, A. Testa, S. Veillon, B. Vendrely, Z. Masoumi, P. Ahmadpoor, S. M. H. Ghaderian, M. Nafar, S. Samavat, F. Samadian, F. Poorrezagholi, M. Shahidi, E. Riccio, B. Visciano, I. Capuano, A. Memoli, G. Mozzillo, B. Memoli, and A. Pisani
Subjects: Transplantation, medicine.medical_specialty, Nephrology, business.industry, Internal medicine, Medicine, business
Published: 2013

9. Improvement of Hepatic Encephalopathy by Application of Peritoneal Dialysis in a Patient with Non-End-Stage Renal Disease

Author: E. Grapsa, K. Pantelias, A. Polydorou, F. Nikolakopoulos, P. Korfiatis, and C. Pipili
Subjects: medicine.medical_specialty, business.industry, medicine.medical_treatment, General Medicine, medicine.disease, Gastroenterology, Peritoneal dialysis, End stage renal disease, Text mining, Nephrology, Internal medicine, medicine, business, Hepatic encephalopathy
Published: 2013

10. Anaphylaxis during rapid oral desensitization to rifampicin

Author: Syrigou, E. Grapsa, D. Nanou, E. Zande, M. Vassias, A. Gkiozos, I. Syrigos, K.
Published: 2016

11. H1N1-induced venous thromboembolic events? Results of a single-institution case series

Author: Dimakakos, E. Grapsa, D. Vathiotis, I. Papaspiliou, A. Panagiotarakou, M. Manolis, E. Syrigos, K.
Subjects: cardiovascular diseases
Abstract: We describe the clinical and imaging characteristics of 7 cases with polymerase chain reaction-confirmed novel influenza A H1N1 virus (pH1N1) infection who developed venous thromboembolic events (VTEs) while being hospitalized for influenza pneumonia. Pulmonary embolism (PE) without deep vein thrombosis (DVT) was observed in 6 of 7 cases (85.7%); PE with underlying DVT was found in 1 patient (14.3%). © 2016 The Author.
Published: 2016

12. Renal anaemia - CKD 5D

Author: K. Takasawa, C. Takaeda, M. Higuchi, T. Maeda, N. Tomosugi, N. Ueda, Y. Sasaki, M. Ikezoe, M. Hagiwara, S. Furuhata, M. Murakami, Y. Shimonaka, S. Yamazaki, S. Hamahata, M. Oue, T. Kuragano, M. Furuta, M. Yahiro, A. Kida, Y. Otaki, Y. Hasuike, H. Nonoguchi, T. Nakanishi, P. Sarafidis, A. Rumjon, D. Ackland, H. Maclaughlin, S. S. Bansal, I. C. Macdougall, V. Panichi, A. Rosati, E. Malagnino, R. Giusti, A. Casani, G. Betti, P. Conti, G. Bernabini, C. Gabrielli, D. Caiani, A. Scatena, M. Migliori, F. Pizzarelli, E. Mitsopoulos, M. Tsiatsiou, I. Minasidis, V. Kousoula, E. Intzevidou, P. Passadakis, V. Vargemezis, D. Tsakiris, S. W. Lines, A. M. Carter, E. J. Dunn, M. J. Wright, R. Aoyagi, T. Miura, L. De Paola, G. Lombardi, G. Coppolino, L. Lombardi, H. Fukumoto, S. Kaibe, M. Tokuyama, M. Hiwasa, T. Miyamoto, H. Ohue, A. Matsumoto, K. Toyoda, J. Rottembourg, C. Emery, A. Lafuma, J. Wernli, L. Zakin, L. Mahi, D. Borzych-Duzalka, Y. Bilginer, L. Pape, I. S. Ha, M. Bak, A. Chua, L. Rees, S. Pesle, F. Cano, A. Urzykowska, S. Emre, J. Russcasso, V. Ramela, N. Printza, C. White, D. Kuzmanovska, V. Andrea, D. Muller-Wiefel, B. Warady, F. Schaefer, J. H. Chung, M. K. Park, H. L. Kim, B. C. Shin, T. Fujikawa, T. Kuji, M. Kakimoto, K. Shibata, H. Satta, M. Nishihara, S. Kawata, N. Koguchi, Y. Toya, S. Umemura, V. David, G. Michel, H. Maxime, L. Paul, K. Sebastien, V. Francois, V. Kuntsevich, Y. Dou, S. Thijssen, N. W. Levin, P. Kotanko, B. S. Kim, W. D. Park, H. C. Song, H. G. Kim, Y.-O. Kim, K. Woodburn, K.-L. Fong, Y. Moriya, Y. Tagawa, F. Kanda, N. Morita, G. London, P. Zaoui, A. Covic, F. Dellanna, D. Goldsmith, L. Gesualdo, J. Mann, C. Combe, M. Turner, M. Meunzberg, K. Macdonald, I. Abraham, A. Guerin, M. Diaconita, R. Apruzzese, A. Kruse, G. Ouellet, C. Bond, D. Jensen, S. Wang, E. Pham, J. Rubin, M. Sika, R. Niecestro, S. Sloneker, P. Strzemienski, E. Solon, D. Stamopoulos, N. Mpakirtzi, E. Grapsa, B. Gogola, E. Manios, N. Afentakis, and J. Ewer
Subjects: Transplantation, medicine.medical_specialty, Nephrology, business.industry, Internal medicine, medicine, Renal anaemia, business
Published: 2012

13. Epithelioid hemangioendothelioma treated with bevacizumab: A case series

Author: Merikas, E. Grapsa, D. Dikoudi, E. Gkiozos, I. Boura, P. Charpidou, A. Kainis, E. Syrigos, K.
Abstract: Introduction: Epithelioid hemangioenthothelioma (EH) is a rare vascular neoplasm of endothelial origin. It most commonly develops in the lung and liver, but may also arise from any organ, and typically displays an intermediate clinical behavior between haemangioma and angiosarcoma. Because of the rarity of this tumor no standard therapy has been proposed. Targeted antiangiogenic therapy using bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been previously reported in very few isolated cases with contradictive results. Presentation of cases: We herein report a case series of four patients with EH, including two cases of localized lung and pleural EH and two cases of liver and bone EH with pulmonary metastases, which were all treated with bevacizumab. Discussion: Among our studied cases, bevacizumab monotherapy was well tolerated and resulted in stable disease in three patients with advanced-stage lung, liver and bone EH, for a period of 11, 7 and 12 months, respectively. Moreover, in one of these cases (primary liver EH with pulmonary metastases), long-term disease stabilization for an additional period of 17 months was observed following administration of chemotherapy with cyclophosphamide, adriamycin and vincristine (CAV) and hepatic arterial chemoembolization combined with thalidomide. Conclusion: Bevacizumab monotherapy at 15. mg/kg may benefit the outcome of patients with advanced EH. We also report a long-term disease stabilization following treatment with CAV and hepatic arterial chemoembolization combined with thalidomide, in a case of liver EH with pulmonary metastases. © 2015 Elsevier Ltd.
Published: 2015

14. Cow's milk protein allergy causing persistent elevation of antitissue transglutaminase antibodies in a child with celiac disease

Author: Merikas, E. Grapsa, D. Syrigos, K. Syrigou, E.
Published: 2015

15. Track C Epidemiology and Prevention Science

Author: E. Munyi, P. Iracheta, W. El Sadr, Thomas L. Patterson, N. McGrath, W. Areekul, J. Konikoff, J.S. Graff-Zivin, J. Valladares, O. Levina, A. Wohl, G. Kirk, C. Nhlapo, S. Hoffman, A. Hughes, S. Bertagnolio, S. Gari, B. Grinsztejn, L. Sherr, C. Mattson, T. Finlayson, M. Schim van der Loeff, J.M. Wekesa, R. Qazi, B. Elul, D. Nsona, B. Le, Margaret Hellard, L. Cottle, G. Kwesigabo, P. Mushati, M. Sangeeth, J.T. Maricato, S. Kippax, W. Aung, M. Yu, A. Ochieng, A. Bennani, I. Massud, K. Kardos, K. Muessig, M. Kato, D.N. Raugi, A. Mkhwanazi, M. Roehler, J. Casillas, G. Rutherford, S.J. Gange, N. Kumarasamy, O. Abaza, H.C. Johnson, J.B.F. de Wit, K. Brady, K. Sigaloff, Colleen F. Kelley, J. Kuruc, Supriya D. Mehta, M. Thrun, G. Likatavicius, K. Muldoon, P. Cherutich, M. Siminyu, C. Scanlon, B. Rodriguez, T. Okeyo Adipo, C. Nyamukapa, D. Reach, M. Morris, I. N'Doye, B. Engelsmann, V. Suwanvanichkij, S. Khobragade, J. Nielsen-Bobbit, J. Mitchell, S. Phillips, C.B. Borkowf, C. Nitrahally Mallachar, D.L. Sodora, T. Guadamuz, Christopher K Fairley, G. Phatedi, V. Tepper, J. Willig, Han-Zhu Qian, K. Underhill, E.R.M. Nunes, E. Machakaire, J. Bouscaillou, M. Boyes, L.D. Chava, M. Taylor, X. Zhang, Charles S. Morrison, V. Sharma, R. Firestone, M.R. Lamb, H. James, S.M. Cohen, H. Crane, J. Coleman, K.W. Ranby, H. Van Renterghem, J. Eckenrode, S. Mwalili, M.H. Ngolobe, J. Mitty, S. Sivalenka, T. Bhatnagar, S. Abel, I. Oumzil, J.R. Lama, E. Connick, S. Kennedy, K. Nielsen-Saines, H. Muyinda, Y.M. Nakamura, P. Thomas, R. Salata, I. Kuo, F. Sall, J. Menten, G. Mkandawire, E. Mills, K.A. Gebo, Rob J. Fredericksen, P. Kasonde, S. Braunstein, Erin M. Kahle, B. Kilama, L. Beer, I. de Beer, N. Elkot, C.K. Cunningham, G. Peytavin, T.-Y. Liu, J.W. Eaton, T. Chuenchitra, Jorge Sanchez, N. Hamunime, R. Grant, J.E. Mantell, T. Mashigo, N. Nazim, N.N. Zheng, B. Cutler, R. Rangsin, N. Knight, A.M. Malone, J. Zaidi, P. Edwards, J.T. Brooks, K. Alami, M.K. Mainkar, A. Kowalski, N. Jack, D. Pieterse, Mark Stoove, M. Mirira, C. Schumacher, A.J. Schmidt, W. Jaoko, C.M. Lowndes, S. Atallah, B. Yang, M. Fox, R. Lebelonyane, B. Feldman, S. Caffe, James Kiarie, A. Simo, E. Kajawo, L. Thomas, T.B. Masvawure, R. Staub, C. Ngoloyi, S. Galea, E.L. Ross, F. Noubary, J. Vanhommerig, S. Patel, S. Khanakwa, L. Hightow-Weidman, S. Braithwaite, P. Perchal, J. Mulilo, C.S. Meade, M. Tsepe, A. Suthar, W. Zule, B. Singh, B. Panchia, L. Yin, J. Skinner, S. Ramanathan, K.M. Gray, H. Ramy, S.M. Graham, M.T. Schechter, H. Zhang, R. Harrison, J.P. Zukurov, A. Gonzalez-Rodríguez, L. Johnston, Maria Prins, T. Smith, S. Stoelzl, N. Siegfried, D. De Angelis, G. Paz-Bailey, D. Taljaard, D. Operario, J.D. Fishel, Dobromir T. Dimitrov, Jared M. Baeten, K.J. Sikkema, A. Urbina, S. Birnel-Henderson, Deborah Donnell, J. Borders, R. Killian, G. Mavise, H. Gamieldien, S. Isac, D. Yang, J. Gunthorp, A. Lansky, K.N. Althoff, M. Vincent, J. Lingappa, Patrick S. Sullivan, M.E.E. Kretzschmar, W. Hanekom, M. De Klerk, C. Odhiambo, J. Shafi, V. Kodali, H. Jackson, S. Bharat, Michael Pickles, R. Geskus, R. Jones, L. Vu, P. Messeri, W. Duffus, R. Limaye, M. Collumbien, G. Allen, E. Elghamrawy, R. Spijker, F. Traore, N. Abdallar, K. Lythgoe, Eli S. Rosenberg, M. van de Laar, S. Stromdahl, A. Bowring, P. Schmid, Grant Colfax, S. Duncan, V. Elharrar, T. Madidimalo, H. Tran Viet, M. Tran Thi, K.E. Nelson, D.C. Sokal, S. Mathew, M. Baum, R. Hari Kumar, Sonia Napravnik, J. Lou, Paula M. Frew, M. Alary, Mari M. Kitahata, Tsungai Chipato, R.C. Berg, I. Maclean, D. Kimanga, Y.T. Duong, L. Jacobson, David R. Bangsberg, F. Odhiambo, A. Malone, G. Wang, E. Schiff, Y. Ding, C. Mlambo, D. Wheeler, J. Martin, A. Kwon, X. Xia, R. Granich, Yuhua Ruan, L.-G. Bekker, Stephen L. Boswell, S. Johnson, F. Njenga, F. Gardner, S. Sherman, Q. Abdool Karim, A. Hoare, K. Thomas, Connie Celum, A. Balaji, L. Metsch, M.J. Mugavero, J. Hahn, J. Denison, M. Kretzschmar, M.R. Lozada, A. Zee, J. Frohlich, P.-L. Chen, D. Vyas, Z.A. Stein, I. Hoffman, S. Weber, S. Abou Elmagd, J. Kriebs, D. Skinner, H. Cross, E. Piwowar-Manning, R. Wiegand, B. Furness, A.C. Voetsch, Q. Awori, S. Kapiga, V. Mugisha, R. Nkambule, F. Tanser, S.E. Hawes, R. Ochai, C. Mathews, Myron Essex, M. Chilila, P. MacPhail, P. Michel, J.H. McMahon, V. Sharp, P. Dupas, M. Schaan, Tonia Poteat, S.A. Kaplan, J. Peinado, L. Zhang, P. Weatherburn, N.M. Fernandes, I. Nieves-Rivera, M. Eberhart, A. Presanis, J. Tejero, A. Pettifor, N. Wadonda, R. Adhikary, S. Shoptaw, K. Page, Nelly Mugo, C. Kuo, D. Cohan, V. Delpech, G.D. Kirk, J. Stover, M. Cohen, V. Cummings, C. Johnson, J. Pilotto, J. Tiffany, S. Rajaram, F. Assouab, V. Akelo, Jeanne M. Marrazzo, Y. Shao, J. Schulden, M. Mahy, Z. Hennessey, A. Sunantarod, S. Meesiri, T. Hallett, J.R. Williams, K. Hayashi, M. Barone, A. La Marca, T. Gamble, J. Moguche, S.Y. Hong, K. Kana, B.R. Santos, Mary S. Campbell, B. Auvert, C.H. Watts, P. Ntshangase, A.M. Foss, A. Anglemyer, P. Li, S.P. Ravi, T.J. Smith, Mark N. Lurie, L. Laurenco, A. Chaturvedula, A.C. Justice, J. Sayles, K. Rou, S. Behel, G. de Bruyn, A. Cescon, S. Pont, Till Bärnighausen, R.A. Willis, D. Forrest, P. Vickerman, A. Cope, M. Eliya, J. Mellors, H.B. Jaspan, J. Grinsdale, Y. Dong, James I. Mullins, R. Detels, N. Roth, J.-A.S. Passmore, S.E. Bradley, R. King, C. Latkin, S. Kandula, E. Wahome, D. Celentano, P. Goswami, B. Tee, A. Thiongo, K. Kaplan, J. Pienaar, M.W. Ross, P. Kaleebu, S. Chariyalertsak, K.F. Kelley, E. Valverde, Susan Scheer, M. Bhattacharya, J. Kinuthia, R. Brookmeyer, E. Mwamburi, A. Castel, G. Trapence, R. Helmy, G. Bicego, Carol El-Hayek, P. Chavez, E. Brown, C. Frangakis, E. Rodríguez-Nolasco, M. Colvin, Stefan Baral, A. Delgado-Borrego, J. Kessler, M.C. Weinstein, H. Shasulwe, B. Koblin, M. Magnus, W. Zhou, M.H. Watt, David Moore, J.B. Reed, C. Debaulieu, M.R. Jordan, F. Martinson, K. Nucifora, P.W. Young, L. Kayla, W. Matthews, M. Motamedi, J. Gweshe, B. El Omari, R. Ondondo, C. Kahlert, X. Cao, J. Okanda, G. Makana, V. Go, R. Colebunders, R. Simba, I. Hall, R. Bakker, P. Vernazza, D. Exner-Cortens, A. Brown, L. Kurtz, K.R. Amico, H. Ntalasha, R. Baggaley, N. Song, T. Aragon, R.S. Hogg, J. Nikisi, F. Mwanga, C. Shepard, O. Koole, K. Buchacz, P. Gonzales, A. Martin, B. Santos, D. Lewis, G. Anderson, C. Polis, S. Derendinger, K. Mayer, S. Vermund, A. Griffin, Samuel R. Friedman, M.S. Cohen, F.J. Muro, D. Patel, A. Sugarbaker, M. Musheke, C. Beyrer, C. Kwok, B.P. Yadav, J. Kaplan, R. Zulz, C. Mullis, R. Bailey, R. Dickson, T. Subramaniam, Katerina A. Christopoulos, K.A. Webb, J. Mbwambo, A. Phillips, M.A. Lampe, M. Muthui, R. Washington, T. Abdalla, J. Margolick, Matthew J. Mimiaga, Helen Rees, H.M.J.P. Vidanapathirana, R. Kamwi, Z. Yin, E.L. Frazier, M. Orkin, M. Beksinska, S.A. Strathdee, Andrea L. Wirtz, S. Elkamhawi, C. Soliman, T. Kerr, G. Pappas, Renee Heffron, S. Bachman, N. Forster, C. Mapanje, M. Goldstein, J. McMahon, P. Nair, J. Banda, M. Kall, R. Fichorova, Nelson K. Sewankambo, W. Zhu, D. Nicca, J.A. Moss, N. Habarta, E.J. Sanders, B. Riggan, P. Roberts, W. Heneine, D. Shabangu, J.L. Burgos, R. Ducharme, M. Toure, G.P. Garnett, R. Arafat, C. Ryan, E. Grapsa, P.M. Spittal, Kenneth Ngure, J. Waldura, M. Hosseinipour, N. Mensah, J. Ellard, T. Tang, R. Smith, J. Grund, R. Wood, Dean Murphy, M.-P. Sy, S. Gregson, R.A. Coutinho, D. Burns, Robert W. Coombs, N. Rafif, J.G. Hakim, S. Sahay, M.-L. Newell, M.L. Ngeruka, S.P. Fiorillo, C.-P. Pau, M. Decker, M. Getahun, E. Eduardo, L. Dumba, Joseph Makhema, T. Crea, J. Schillinger, Y. Jia, M. Sulkowski, Grace John-Stewart, F. Mbofana, Sam Phiri, N.B. Kiviat, B.P.X. Grady, V. Cambiano, T. Friel, David E Leslie, Y. Gebre, N. Muraguri, L. Valleroy, J. Skarbinski, P. Nadol, C. Kerr, T. Brewer, A. Ghani, M. Chen, L. Mills, S. Mital, C. Qiu, A.D. Paltiel, Janet J. Myers, C. van Gemert, R. Panchia, S. Agolory, A. Koler, P. Dietze, A. Jonas, N. Taruberekera, N. Philip, S.R. Nesheim, S. Tsui, J.P. Bitega, R. Abdool, C. Nekesa, J.G. Kahn, S. Townsell, S. Chan, A. Mujugira, V. Capo-Chichi, P. Rebeiro, Y. van Weert, J. Limba, K. Morrow, J. Birungi, E. Van Praag, L. Juárez-Figueroa, W. Miller, L.X. Deng, D. MacKellar, D. Kiima, V.D. Ojeda, P.L. Chu, S. Ohaga, J. Bradley, T. Sripaipan, C. Nguyen, R. Coutinho, E. Gardner, K.L. Vincent, A. Surendera Babu, A. Pharris, N. He, M. Maskew, S. Moses, A. Khan, H. Wang, M. Akello, Brandon O'Hara, J. Evans, D.E. Bennett, G.F. Webb, U. Abbas, C. Pretorius, M. Egger, R.S. Gupta, M. Mulenga, M. Odiit, C.E. Jones, M.F. Schim van der Loeff, I. Shaikh, A.D. Smith, D. Mark, G. Otieno, M. van Rooijen, T. Exner, A. Aghaizu, A. Vu, T. Ahmed, M. Wolverton, L. Seemann, Gustavo F. Doncel, A. Kharsany, C. Botao, J. Brown, J. Eaton, D. Krakower, J. Justman, Sheryl A. McCurdy, J. Otchere Darko, I. Denham, S. Fields, T. Taha, V. Jumbe, Z. Mwandi, K. Sey, T. Webster-León, M.A. Chiasson, W. Burman, E. Daniel, F. Deyounks, R. Willis, C. Kunzel, B. Greenberg, M. Lalota, B. George, R. Sitta, S. Abdool Karim, M. Kganakga, N. van der Knaap, S. Griffith, Z. Wu, C. del Rio, A. Briceno, R.P. Walensky, M.G. Anderson, Q. Vu Minh, R. Cabello, J.R.S. Malungo, H.J. Prudden, M. Mulatu, Y.Q. Chen, M.M. Baum, F. Mawazini, G. Phillips, B. Williams, F. van Aar, T. Noori, K. Curtis, L. Cluver, S. Huang, S. Safren, N. Westercamp, M. Pereyra, B. Nichols, L. Robertson, A. Oster, G. Kamanga, I. Butkyavichene, S. Ketende, W. Dothi, T. van de Laar, S. Bodika, L. Pang, S.J. de Vlas, B. Bearnot, M. Wallace, E. Duflo, F.M. Chimbwandira, L. Ramakrishnan, W. Kanjipite, A. Del Riego, S. Willis, S.L. Cherne, S. Merten, D. Hoover, A.K. Hesseling, E. Daniloff, K. Agot, L. Wang, Y. Ma, T. Heijman, Marie-Claude Boily, Susan Buchbinder, N. Luhmann, A.E. Phillips, D. Kamba, E. Op de Coul, L.M.R. Janini, M. Kolber, D. Reirden, G. Osorio, S.C. Kalichman, S. Combes, A. Auld, J. Rosenberger, H. Lin, A.S. de Vos, M. Paczkowski, E. Pouget, W. Davis, C. Mauck, M. Berry, S. Godbole, S. Mannheimer, N. Bock, C. Sexton, O. Whiteside, A. Bocour, S.K. Mohammed, J.G. Garcia-Lerma, T. Quinn, E. Losina, J.H.d.S. Pilotto, L. Werner, D. Newman, K. Russell, M. Chakela, S. Rowan, E. Wood, K.M. Mitchell, D. Novak, S. Rao, S. Roux, L. Ti, Edwin Were, J. Moss, G. Seage, A. Wongthanee, A. Muadinohamba, A. Crooks, X. Li, W. Motta, Noah Kiwanuka, M. McCauley, M.G. Rangel, G. Ravasi, B. Pick, T. West, R.N. Rimal, K. Bowa, J. Xu, P. Rhodes, J. Thorne, C. Avila, Michael S. Saag, E.A. Kelvin, A. Nqeketo, G.-M. Santos, H. El Rhilani, G.S. Gottlieb, N. Wang, S. Williams, I. Halldorsdottir, L.P. Jacobson, O. Mellouk, M. Sweat, L.R. Metsch, K. Sabin, S. Philip, S. Badal-Faesen, G. Sal y Rosas, D.H. Evans, R. Kumari, B. Tempalski, H.S. Okuku, I. Sanne, R.D. Moore, Y. Wang, A. Mbandi, S. Messinger, I. Balan, K. Kahuure, D. Kerrigan, J.J. van der Helm, D.L. Ellenberger, S.E. Kellerman, M. Sweeney, J. Opoku, H. Ginindza, D. Suryawanshi, N. Kikumbih, B.S. Parekh, J. Heffelfinger, C. Hart, B. Marshall, M. Jordan, O. Laeyendecker, O.N. Gill, S. Lee, G.R. Seage, C.-C. Udeagu, Travis Sanchez, J. White, J. Mwambi, J. Gilman, J. Talley, R. Baltussen, P. Galatowitsch, Kenneth H. Fife, T.R. Sterling, C. Mao, T. Frasca, A. Speksnijder, M. Nguyen Le, E. Dinenno, S. Kawichai, S. Hong, A. Gagner, L. Ouarsas, J. Goller, C. Watson, E. White, R. Monasch, N. Chotirosniramit, L. McNamara, D. van de Vijver, V. Hu, Sarah E. Rutstein, R. Glaubius, R.S. Paranjape, J. Peterson, P. Swain, Johnstone Kumwenda, Elizabeth A. Bukusi, F. Wabwire-Mangen, A. Buchanan, K.A. Freedberg, K. Shannon, J.C. Makoni, N. Rosenberg, J. Montaner, R. Koul, J. Zhang, E. Shihepo, J. Wang, H. Tran Vu, J.A. Smit, M. Sinunu, K. Chesang, G. Muzaaya, E.J. Schouten, V. Joseph, C. Karema, B.M. Ramesh, J.A.C. Hontelez, K. Torpey, G. Guillon, R. Taljaard, J. Elliott, R. Rao, D. Wilson, T.B. Hallett, Y.D. Mukadi, D.R. Holtgrave, K. Yotruean, M. Rasi, K.H. Mayer, M. Horberg, C. Chariyalertsak, C.-S. Leu, S. Billy, R. Lee, P. Suwannawong, Barrot H. Lambdin, R. Heimer, J. Tosswill, Marsha Rosengarten, A. Tripathi, M. Williams-Sherlock, C. Dolezal, M. Makhanya, A.T. Urbanus, C. Hendrix, C. Mwangi, P. Srikantiah, W. Jimbo, A. Puren, T. Smolskaia, M. Kamal, H. Li, G. Murphy, P. Masson, N. Benbow, E. Umar, A. Binagwaho, Papa Salif Sow, P. Lissouba, G. Olilo, P. Pathela, M. Mugavero, M. Cousins, S. Swindells, D. Callander, Z. Mabude, G. Cardenas, M.B. Klein, D. Sherard, C. Toohey, M. Holt, A. Pandey, D. Hedeker, Kimberly A. Powers, J. Astemborski, R. Gregg, M. Cribbin, Edith Nakku-Joloba, C. Furlow-Parmley, A. Abadie, Joseph J. Eron, D. Stéphanie, E. Kersh, P. Oyaro, P. Kohler, D.B. Hanna, H. Götz, H.I. Hall, S. Eshleman, K. Eritsyan, A. Carballo-Diéguez, G. Mujaranji, R. Needle, L. Lacroix, S. Singh, L. Wilton, J. Gallant, A. Howard, H.A. Pollack, J. Mermin, J. Schinkel, and S. Lovelace
Subjects: medicine.medical_specialty, 030505 public health, business.industry, Gonorrhea, Public Health, Environmental and Occupational Health, Human immunodeficiency virus (HIV), Miami, medicine.disease_cause, medicine.disease, Virology, 03 medical and health sciences, Cross matching, 0302 clinical medicine, Infectious Diseases, Family medicine, Medicine, 030212 general & internal medicine, 0305 other medical science, business
Published: 2012

16. Is the underutilization of peritoneal dialysis in relation to hemodialysis, as renal replacement therapy, justifiable worldwide? Yes or No

Author: E, Grapsa
Subjects: Review Article
Abstract: Peritoneal dialysis is the most important home dialysis treatment for end stage renal diseases and needs personal involvement, and support from the family . Peritoneal dialysis presented a number of discouraging technical problems and led to the belief that PD was not an appropriate renal replacement therapy, for patients with end stage renal disease. Despite the improvement of the method its rate remain low (11%) worldwide. The factors affecting the choice of PD are multiple and explain the disparity in the use of peritoneal dialysis in different countries and different parts of the same country. Dialysis costs and reimbursement structures are significant in decisions about the rates and modalities of renal replacement therapy. Late referral and the health care system seems to be very important factors that influence the dialysis modality choice. After the initiation of peritoneal dialysis we can see other factors that influence the survival of the method. The rate of peritonitis and the peritoneum function seems to be important issues.
Published: 2011

17. Bone mineral density and bone metabolism in hemodialysis patients. Correlation with PTH, 25OHD3 and leptin

Author: A, Polymeris, K, Doumouchtsis, and E, Grapsa
Subjects: Adult, Leptin, Male, Bone Density, Parathyroid Hormone, Renal Dialysis, Humans, Female, Middle Aged, Bone and Bones, Aged, Calcifediol
Abstract: Bone metabolism disorders in hemodialysed patients (HD) involve several humoral factors, of which PTH plays the central role. Leptin is usually found increased in renal failure and its link with bone metabolism has not been elucidated. We investigated the BMD and bone metabolism in association with serum PTH, 25OHD3 and leptin in HD patients.We measured bone alkaline phosphatase (bSAP), cross linked N telopeptide of type 1 collagen (NTx), PTH, 25OHD3 and leptin in 37 HD patients. We also evaluated BMI and BMD in lumbar spine (LS) and in femoral neck (FN) by DXA. Statistical evaluations were based on simple regression analysis.1) Osteopenia was found in 32,1% in LS and 50% in FN and osteoporosis in 14.3% and 21.4% of our patients, respectively. LS or FN Z score was not related to HD duration. 2) Bone markers, PTH, phosphorus and leptin levels were increased. 3) 25OHD3 was low and was not related to NTx, bSAP or PTH. 4) PTH correlated with bone markers and Z score in LS and FN. 5) Leptin had no correlation with bone markers or Z score (except BMI).In our hemodialysed patients bone metabolism markers were increased in relation with high serum PTH levels. The observed high serum leptin was not associated with bone metabolism. Additionally the duration of hemodialysis did not appear to affect bone density.
Published: 2011

18. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: Dosing of lenalidomide according to renal function and effect on renal impairment

Author: Dimopoulos, M.A. Christoulas, D. Roussou, M. Kastritis, E. Migkou, M. Gavriatopoulou, M. Matsouka, C. Mparmparoussi, D. Psimenou, E. Grapsa, I. Efstathiou, E. Terpos, E.
Abstract: Objectives: Lenalidomide and dexamethasone (LenDex) is an active regimen for relapsed/refractory multiple myeloma (MM). However, there is limited data for the effect of LenDex on renal impairment (RI) and on renal reversibility. Patients & Methods: Fifty consecutive patients with relapsed/refractory MM received LenDex in 28-d cycles. Median lines of previous therapies were 2 (range: 1-6). Lenalidomide was administered on days 1-21 according to creatinine clearance (CrCl), while dexamethasone was given at a dose of 40 mg on days 1-4 and 15-18 for the first four cycles and only on days 1-4 thereafter. Results: Twelve patients (24%) had RI at baseline, defined as CrCl < 50 mL/min. Most patients were pretreated with either thalidomide or bortezomib and > 50% of them were refractory to both drugs. At least partial response was documented in 60.5% and 58% of patients with and without RI. Median progression-free survival (PFS) and overall survival (OS) for all patients was 9 and 16 months, respectively. RI was not associated with an inferior PFS or OS. There were no differences in the incidence of adverse events among patients with and without RI. Three of 12 patients with RI (25%) achieved complete renal response and two (16%) achieved minor renal response with LenDex. Conclusions: We conclude that LenDex is an active treatment even in heavily pretreated MM. With dosing of lenalidomide according to renal function, LenDex can be administered to patients with RI (who may not have other treatment options) without excessive toxicity. Furthermore, LenDex may improve the renal function in approximately 40% of patients with RI. © 2010 John Wiley & Sons A/S.
Published: 2010

19. Ascitic fluid cytology of yolk sac tumor of the ovary: A case report

Author: Petrakakou, E. Grapsa, D. Stergiou, M.-E. Mikou, P. Tsarpalis, D. Polyzos, A. Giahnaki, A. Ioakim-Liossi, A.
Abstract: Background: Yolk sac tumor (YST) of the ovary is a rare neoplasm typically affecting children and young women. We describe the cytomorphology of this tumor in ascitic fluid and discuss its differential diagnosis from other neoplasms. Case: Smear preparations of the ascitic fluid showed a predominance of clusters of malignant cells with vacuolated cytoplasm, mimicking a mucinous adenocarcinoma, and fewer syncytial-like and glandular structures. Hyaline globules were extremely rare. lmmunocytochemistry was positive for α-fetoprotein. Conclusion: The diagnosis of YST in ascitic fluid specimens may be challenging and requires the use of immunocytochemistry and the correlation of cytology with the remaining clinical and laboratory data. © The International Academy of Cytology.
Published: 2009

20. Chronic Peritoneal Dialysis in the Elderly

Author: E. Grapsa and D. G. Oreopoulos
Published: 2009

21. The expression of metallothioneins on imprint smears of prostate carcinoma: Correlation with clinicopathologic parameters and tumor proliferative capacity

Author: Athanassiadou, P. Bantis, A. Gonidi, M. Athanassiades, P. Agelonidou, E. Grapsa, D. Nikolopoulou, P. Patsouris, E.
Abstract: Aims and background: Metallothioneins are a family of metal-binding cysteine-rich proteins that play an important role in cellular processes such as proliferation and apoptosis, protection against oxidative stress and metal ion homeostasis and detoxification. Recent findings suggest that metallothioneins might play a significant role in the development and progression of prostate cancer. It has been also demonstrated that Ki-67 expression may have prognostic value for disease-free survival in cases of prostate carcinoma. Study design: Imprint smears samples obtained from 70 patients immediately after radical prostatectomy for prostatic carcinoma were immunostained with monoclonal antibodies against metallothioneins and Ki-67. Metallothionein expression was correlated with Ki-67 immunostaining, Gleason score, stage, preoperative prostate-specific antigen levels and biochemical recurrence. Results: Metallothionein expression was shown to correlate strongly with Gleason score (P
Published: 2007

22. Effect of dialysis on plasma total antioxidant capacity and lipid peroxidation products in patients with end-stage renal failure

Author: E. Grapsa and E. Samouilidou
Subjects: Adult, Male, medicine.medical_specialty, Antioxidant, medicine.medical_treatment, Oxidative phosphorylation, medicine.disease_cause, Antioxidants, Peritoneal dialysis, Lipid peroxidation, chemistry.chemical_compound, Renal Dialysis, Internal medicine, Malondialdehyde, medicine, Humans, Dialysis, Aged, business.industry, Hematology, General Medicine, Middle Aged, medicine.disease, Oxidative Stress, Endocrinology, chemistry, Nephrology, Case-Control Studies, Kidney Failure, Chronic, Female, Hemodialysis, Lipid Peroxidation, business, Oxidative stress, Kidney disease
Abstract: Dialysis is associated with an impairment of antioxidant defense and an overproduction of oxidative stress markers. This study focuses on the comparison of plasma total antioxidant capacity (TAC) and lipid peroxidation products in patients on hemodialysis (HD) before and after treatment and in peritoneal dialysis (PD) patients. Plasma TAC, malonaldehyde (MDA), and 4-hydroxyalkenal concentrations were measured in 31 HD patients, in 24 PD patients, and in 17 normal controls (NC). It was found that before HD, TAC and MDA levels were higher than those in the NC (p < 0.001). After HD, these levels decreased significantly but were higher than in NC and lower than in PD patients (p < 0.001). The levels of 4-hydroxyalkenals were elevated in patients as compared with NC, but did not differ between HD and PD patients. The MDA concentrations correlated positively with the TAC in the patients. It is concluded that the oxidative status of patients on HD is similar to that of patients on PD and that the susceptibility to oxidative stress is strongly related to the levels of MDA produced in plasma.
Published: 2003

23. Association of serum nitric oxide levels with depressive symptoms: a study with end-stage renal failure patients

Author: Charalabos Papageorgiou, Nikos G. Christodoulou, S. Stamatelopoulos, E. Grapsa, N. Zerefos, and G.N. Christodoulou
Subjects: Adult, Male, medicine.medical_specialty, Personality Inventory, medicine.medical_treatment, Metabolite, Disease, Nitric Oxide, Nitric oxide, chemistry.chemical_compound, Weight loss, Renal Dialysis, Internal medicine, medicine, Humans, Applied Psychology, Depression (differential diagnoses), chemistry.chemical_classification, business.industry, Depression, Sick Role, General Medicine, Middle Aged, medicine.disease, Psychiatry and Mental health, Clinical Psychology, Enzyme, Endocrinology, chemistry, Kidney Failure, Chronic, Female, Hemodialysis, medicine.symptom, business, Kidney disease
Abstract: Background: Nitric oxide (NO) is a soluble gas produced by the activity of an enzyme found in neurons. It has been implicated in a great number of normal physiological functions (such as noradrenaline and dopamine release, memory and learning, regulation of the cerebrovascular system, modulation of wakefulness, modulation of nociception, olfaction, food intake and drinking) as well as pathologies (Alzheimer’s, Huntington’s disease, cerebral ischemia, stroke). Two reports have addressed the involvement of NO in depression. Methods: The objective of the study was to examine the association between NO and specific depressive symptoms. For this purpose, in a sample of 28 end-stage renal failure patients (who have increased NO levels), we tested the hypothesis that the subgroup of patients with these specific depressive symptoms was differentiated from the patients without these symptoms with regard to serum levels of NO metabolites. The depressive symptoms were assessed using the Zung self-rating scale. Results: Our study revealed an association of NO with the following depressive symptoms: sexual dysfunction, weight loss, psychomotor retardation, indecisiveness and irritability. Conclusion: The association between NO system and symptoms of depression does not necessarily imply a pathogenetic association between NO and depressive disorder. Further research is needed to verify these findings and study their possible pathogenetic implications.
Published: 2001

24. Continuous ambulatory peritoneal dialysis in the elderly

Author: D. G. Oreopoulos and E. Grapsa
Subjects: education.field_of_study, Pediatrics, medicine.medical_specialty, business.industry, medicine.medical_treatment, Population, Continuous ambulatory peritoneal dialysis, Dialysis patients, Peritoneal dialysis, Esrd patient, medicine, Renal replacement therapy, education, business, Dialysis
Abstract: Commonly an individual is designated as elderly at 65 years. During this century the number of people living beyond age 65 has increased. In 1900 only 4% of the Western world’s population was over 65 years of age, but now this fraction is 12% and rising [1]. By the year 2040, 21% of the population in the United States will be over 65, and by the year 2050 one in 20 people in the USA will be older than 85 [2, 3]. This progressive increase in the elderly and the success of dialysis have produced a dramatic increase in the numbers of elderly dialysis patients worldwide. Thus, in the USA 47% of those on dialysis are over 65; this fraction is expected to increase to over 60% by the end of this century [4–6]. In Canada, in 1989, 35% of end-stage renal disease (ESRD) patients were over the age of 65 compared to 25% in 1981 [7]. In 1990, in a UK dialysis centre that provides the sole nephrological service for a population of 1.2 million people, those over 65 constituted more than 25% of all new patients accepted for dialysis [8]. The European Renal Association Registry has reported a similar trend. In 1977 only 9% of those patients starting renal replacement therapy were older than 65 years; in 1980, 11%; in 1983, 30%; whereas by 1992 this population had increased to nearly 37% [9, 10]. Thus, elderly patients, who previously were excluded from dialysis, now are the fastest-growing segment of the dialysis population [10, 11].
Published: 2000

25. Uremic pruritus is a poor prognostic factor of outcome

Author: E V, Balaskas and E, Grapsa
Subjects: Male, Peritoneal Dialysis, Continuous Ambulatory, Renal Dialysis, Pruritus, Humans, Female, Middle Aged, Prognosis, Uremia
Published: 1995

26. Elderly dialysis patients: some do quite well

Author: E, Grapsa and D G, Oreopoulos
Subjects: Renal Dialysis, Quality of Life, Humans, Karnofsky Performance Status, Aged
Published: 1994

27. Extracorporeal dialysis: techniques and adequacy

Author: C. Donadio, A. Kanaki, A. Martin-Gomez, S. Garcia, M. Palacios-Gomez, D. Calia, E. Colombini, F. DI Francesco, S. Ghimenti, M. Onor, D. Tognotti, R. Fuoco, E. Marka-Castro, M. I. Torres Zamora, J. Giron-Mino, M. A. Jaime-Solis, L. M. Arteaga, H. Romero, A. Akonur, K. Leypoldt, M. Asola, B. Culleton, S. Eloot, G. Glorieux, N. Nathalie, R. Vanholder, A. Perez de Jose, U. Verdalles Guzman, S. Abad Esttebanez, A. Vega Martinez, D. Barraca, C. Yuste, L. Bucalo, A. Rincon, J. M. Lopez-Gomez, P. Bataille, P. Celine, A. Raymond, G. Francois, L. Herve, D. Michel, R. Jean Louis, F. Zhu, P. Kotanko, S. Thijssen, N. W. Levin, N. Papamichail, M. Bougiakli, C. Gouva, S. Antoniou, S. Gianitsi, A. Vlachopanou, S. Chachalos, K. Naka, D. Kaarsavvidou, K. Katopodis, L. Michalis, K. Sasaki, K. Yasuda, M. Yamato, A. Surace, P. Rovatti, D. Steckiph, R. Bandini, S. Severi, A. Dellacasa Bellingegni, A. Santoro, M. Arias, A. Sentis, N. Perez, N. Fontsere, M. Vera, N. Rodriguez, C. Arcal, N. Ortega, F. Uriza, A. Cases, F. Maduell, S. R. Abbas, P. Georgianos, P. Sarafidis, P. Nikolaidis, A. Lasaridis, A. Ahmed, H. Kaoutar, B. Mohammed, O. Zouhir, P. Balter, N. Ginsberg, P. Taylor, T. Sullivan, L. A. Usvyat, P. Zabetakis, U. Moissl, M. Ferrario, F. Garzotto, P. Wabel, D. Cruz, C. Tetta, M. G. Signorini, S. Cerutti, A. Brendolan, C. Ronco, J. Heaf, M. Axelsen, R. S. Pedersen, H. Amine, Z. Oualim, A. L. Ammirati, N. K. Guimaraes de Souza, T. Nemoto Matsui, M. Luiz Vieira, W. A. Alves de Oliveira, C. H. Fischer, F. Dias Carneiro, I. J. Iizuka, M. Aparecida de Souza, A. C. Mallet, M. C. Cruz Andreoli, B. F. Cardoso Dos Santos, L. Rosales, Y. Dou, M. Carter, A. Testa, L. Sottini, B. Giacon, E. Prati, C. Loschiavo, M. Brognoli, C. Marseglia, A. Tommasi, L. Sereni, G. Palladino, S. Bove, G. Bosticardo, E. Schillaci, P. Detoma, R. Bergia, J. W. Park, S. J. Moon, H. Y. Choi, S. K. Ha, H.-C. Park, Y. Liao, L. Zhang, P. Fu, H. Igarashi, N. Suzuki, S. Esashi, I. Masakane, V. Panichi, G. De Ferrari, S. Saffiotti, A. Sidoti, M. Biagioli, S. Bianchi, P. Imperiali, C. Gabrielli, P. Conti, P. Patrone, G. Rombola, V. Falqui, C. Mura, A. Icardi, A. Rosati, F. Santori, A. Mannarino, A. Bertucci, J. Jeong, O. K. Kim, N. H. Kim, M. Bots, C. Den Hoedt, M. P. Grooteman, N. C. Van der Weerd, A. H. A. Mazairac, R. Levesque, P. M. Ter Wee, M. J. Nube, P. Blankestijn, M. A. Van den Dorpel, Y. Park, J. Jeon, N. Tessitore, V. Bedogna, D. Girelli, L. Corazza, P. Jacky, Q. Guillaume, B. Julien, W. Marcinkowski, M. Drozdz, A. Milkowski, T. Rydzynska, T. Prystacki, R. August, E. Benedyk-Lorens, K. Bladek, J. Cina, G. Janiszewska, A. Kaczmarek, T. Lewinska, M. Mendel, M. Paszkot, E. Trafidlo, M. Trzciniecka-Kloczkowska, A. Vasilevsky, G. Konoplev, O. Lopatenko, A. Komashnya, K. Visnevsky, R. Gerasimchuk, I. Neivelt, A. Frorip, M. Vostry, J. Racek, D. Rajdl, J. Eiselt, L. Malanova, U. Pechter, A. Selart, M. Ots-Rosenberg, D. H. Krieter, S. Seidel, K. Merget, H.-D. Lemke, C. Wanner, B. Canaud, A. Rodriguez, A. Morgenroth, K. Von Appen, G.-P. Dragoun, R. Fluck, D. Fouque, R. Lockridge, Y. Motomiya, Y. Uji, T. Hiramatsu, Y. Ando, M. Furuta, T. Kuragano, A. Kida, M. Yahiro, Y. Otaki, Y. Hasuike, H. Nonoguchi, T. Nakanishi, M. Sain, V. Kovacic, D. Ljutic, J. Radic, I. Jelicic, S. F. Yalin, S. Trabulus, A. S. Yalin, M. R. Altiparmak, K. Serdengecti, A. Ohtsuka, K. Fukami, K. Ishikawa, R. Ando, Y. Kaida, T. Adachi, K. Sugi, S. Okuda, O. B. Nesterova, E. D. Suglobova, R. V. Golubev, A. N. Vasiliev, V. A. Lazeba, A. V. Smirnov, K. Arita, E. Kihara, K. Maeda, H. Oda, S. Doi, T. Masaki, S. Hidaka, K. Ishioka, M. Oka, H. Moriya, T. Ohtake, S. Nomura, S. Kobayashi, S. Wagner, A. Gmerek, J. Wagner, V. Wizemann, N. Eftimovska - Otovic, K. Spaseska-Gjurovska, S. Bogdanovska, E. Babalj - Banskolieva, M. Milovanceva, R. Grozdanovski, A. Pisani, E. Riccio, A. Mancini, P. Ambuhl, S. Astrid, P. Ivana, H. Martin, K. Thomas, R. Hans-Rudolf, A. Daniel, K. Denes, M. Marco, R. P. Wuthrich, S. Andreas, S. Andrulli, P. Altieri, G. Sau, P. Bolasco, L. A. Pedrini, C. Basile, S. David, M. Feriani, P. E. Nebiolo, R. Ferrara, D. Casu, F. Logias, R. Tarchini, F. Cadinu, M. Passaghe, G. Fundoni, G. Villa, B. R. DI Iorio, C. Zoccali, F. Locatelli, M. Hamamoto, D.-Y. Lee, B. Kim, K. H. Moon, Z. LI, P. Ahrenholz, R. E. Winkler, G. Waitz, H. Wolf, G. Grundstrom, M. Alquist, M. Holmquist, A. Christensson, P. Bjork, M. Abdgawad, L. Ekholm, M. Segelmark, C. Corsi, J. De Bie, E. Mambelli, D. Mortara, D. Arroyo, N. Panizo, B. Quiroga, J. Reque, R. Melero, M. Rodriguez-Ferrero, P. Rodriguez-Benitez, F. Anaya, J. Luno, A. Ragon, A. James, P. Brunet, S. Ribeiro, M. S. Faria, S. Rocha, S. Rodrigues, C. Catarino, F. Reis, H. Nascimento, J. Fernandes, V. Miranda, A. Quintanilha, L. Belo, E. Costa, A. Santos-Silva, J. Arund, R. Tanner, I. Fridolin, M. Luman, C. Clajus, J. T. Kielstein, H. Haller, P. Libutti, P. Lisi, L. Vernaglione, F. Casucci, N. Losurdo, A. Teutonico, C. Lomonte, C. Krisp, D. A. Wolters, M. Matsuyama, T. Tomo, K. Ishida, K. Matsuyama, T. Nakata, J. Kadota, M. Caiazzo, E. Monari, A. Cuoghi, E. Bellei, S. Bergamini, A. Tomasi, T. Baranger, P. Seniuta, F. Berge, V. Drouillat, C. Frangie, E. Rosier, W. Labonia, A. Lescano, D. Rubio, N. Von der Lippe, J. A. Jorgensen, T. B. Osthus, B. Waldum, I. Os, M. Bossola, E. DI Stasio, M. Antocicco, L. Tazza, I. Griveas, A. Karameris, P. Pasadakis, V. Savica, D. Santoro, S. Saitta, V. Tigano, G. Bellinghieri, S. Gangemi, R. Daniela, I. A. Checherita, A. Ciocalteu, I. A. Vacaroiu, A. Niculae, E. Stefaniak, I. Pietrzak, D. Krupa, L. Garred, E. Mancini, L. Corrazza, M. Atti, B. Afsar, D. Stamopoulos, N. Mpakirtzi, B. Gogola, M. Zeibekis, D. Stivarou, M. Panagiotou, E. Grapsa, O. Vega Vega, D. Barraca Nunez, M. Fernandez-Lucas, A. Gomis, J. L. Teruel, S. Elias, C. Quereda, L. Hignell, S. Humphrey, N. Pacy, and N. Afentakis
Subjects: Transplantation, medicine.medical_specialty, Extracorporeal Dialysis, Nephrology, business.industry, Uremic toxins, Medicine, Identification (biology), business, Intensive care medicine, Microbiology
Published: 2011

28. Association between depressive symptoms and olfactory identification performance. A study with end-stage renal failure patients

Author: Charalabos Papageorgiou, Nikos G. Christodoulou, G.N. Christodoulou, E. Grapsa, and E Emmanouilidou
Subjects: Psychiatry and Mental health, Clinical Psychology, medicine.medical_specialty, business.industry, End stage renal failure, Internal medicine, medicine, Identification (biology), business, Association (psychology), Depressive symptoms
Published: 2003

29. Uremic Pruritus is a Poor Prognostic Factor of Outcome

Author: EV Balaskas and E. Grapsa
Subjects: medicine.medical_specialty, Prognostic factor, Uremic pruritus, business.industry, medicine.medical_treatment, General Medicine, medicine.disease, Gastroenterology, Outcome (game theory), Peritoneal dialysis, Nephrology, Internal medicine, medicine, business
Published: 1995

30. Reactive Oxygen Metabolites: A Link between Oxidative Stress and Inflammation in Patients on Hemodialysis.

Author: E. Samouilidou, E. Grapsa, A. Karpouza, and A. Lagouranis
Subjects: *OXIDATIVE stress, *HEMODIALYSIS patients, *INFLAMMATION, *C-reactive protein, *PEROXIDATION, *REACTIVE oxygen species
Abstract: AbstractOxidative stress plays a significant role in the development of inflammation in patients undergoing hemodialysis (HD). This study intends to evaluate the relationship between C-reactive protein (CRP) and the newly established marker of lipid peroxidation, d-ROMs (reactive oxygen metabolites), in comparison with different indicators of oxidative stress. Plasma total antioxidant capacity (TAC), lipid peroxidation products malonaldehyde (MDA) and 4-hydroxyalkenals, as well as d-ROMs, were determined in 24 patients before HD and in 21 normal controls (NC). It was found that HD patients had higher levels of d-ROMs than NC (p = 0.033). A highly significant positive correlation was observed between logCRP and d-ROMs concentrations (p < 0.0001, r = 0.85) in patients, but not in NC. The concentrations of TAC and MDA were not associated with CRP in HD or in NC individuals. It is concluded that d-ROMs concentration is a potent marker of oxidative injury that is strongly indicative of the inflammatory status in HD patients.Copyright © 2007 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
Published: 2007
Full Text: View/download PDF

31. Erythropoietin Effect on Complement Activation in Chronic Kidney Disease.

Author: Athanasiadou V, Ampelakiotou K, Grigoriou E, Psarra K, Tsirogianni A, Valsami S, Pittaras T, Grapsa E, and Detsika MG
Abstract: The complement system is an important part of innate immunity. Despite its known protective role, the complement system may contribute to increased inflammation and tissue injury in cases where its balanced activation is disrupted. The kidneys have been shown to be largely affected by complement dysregulation. The aim of the present study was to investigate the effect of erythropoietin administration, on the complement system, in chronic kidney disease patients. The study involved 20 patients with CKD who received erythropoietin and measurements of levels of complement factors C3a and C5a and complement regulatory proteins (CregPs) CD55, CD46, and CD59. An increase in serum C3a and C5a levels was observed in response to EPO therapy. The increase in C3a was statistically significant ( p < 0.05) and concurrent with a statistically significant decrease in CD55 in CD4 + T cells ( p < 0.05) and B cells ( p < 0.05) and CD59 levels in CD4 + and CD8 + T cells ( p < 0.05) at completion of EPO therapy compared with healthy controls. The above observations demonstrate that EPO induces complement activation in patients undergoing EPO therapy with a simultaneous restriction of CRegPs expression, thus possibly allowing the uncontrolled complement activation, which may contribute to tissue injury and disease progression.
Published: 2024
Full Text: View/download PDF

32. Investigation of Social Constraints, Psychosocial Adjustment and Optimism among Dialysis Patients.

Author: Zorba E, Fasoi G, Grapsa E, Zartaloudi A, Polikandrioti M, Alikari V, Stavropoulou A, Dafogianni C, Impis O, and Gerogianni G
Abstract: Background: Social constraints are perceived as unsupportive behaviors, leading to inadequate psychosocial adjustment, while optimism can help people recover from distress and reduce any negative effects of chronic disease. The aim of this study was to investigate social constraints, psychosocial adjustment and optimism among patients on dialysis., Methods: In this study, 402 patients undergoing dialysis in Greece completed the following questionnaires: (i) the Social Constraints Scale (SCS) for the assessment of social constrains, (ii) the Psychosocial adjustment to illness scale (PAIS-SR) for the assessment of psychosocial adjustment, and (iii) the LOT-R scale for the assessment of optimism. A Mann-Whitney test was used for the comparison of continuous variables between two groups. Spearman correlation coefficients (rho) were used to explore the association of two continuous variables. Multiple linear regression analysis was used with the SCS scale., Results: Greater difficulty in psychosocial adjustment in the domestic, vocational, extended family and social environments, sexual relationships, and health care as well as greater psychological distress were significantly associated with a greater occurrence of social constraints ( p < 0.001). Additionally, greater optimism was significantly associated with fewer social constraints and lower difficulty in adjusting to their disease ( p < 0.001)., Conclusions: Greater difficulty in all dimensions of psychosocial adjustment is associated with more social constraints, while optimism is associated with fewer social constraints and better disease adjustment.
Published: 2024
Full Text: View/download PDF

33. The importance of paraoxonase 1 activity in chronic kidney disease.

Author: Samouilidou EC, Liaouri A, Kostopoulos V, Nikas D, and Grapsa E
Subjects: Humans, Biomarkers blood, Polymorphism, Genetic, Cardiovascular Diseases etiology, Kidney Transplantation, Atherosclerosis etiology, Prognosis, Aryldialkylphosphatase metabolism, Aryldialkylphosphatase genetics, Aryldialkylphosphatase blood, Renal Insufficiency, Chronic complications, Oxidative Stress
Abstract: Paraoxonase 1 (PON1) is one of the most significant antioxidative enzymes associated with high-density lipoprotein (HDL). It has been proved that is involved in the pathogenesis of many diseases including chronic kidney disease (CKD). The association between PON1 and CKD seems to be mutual, such that the disease produces a significant decrease in PON1 activity levels, while the genetics of PON1 may affect the risk of susceptibility to CKD. Recent studies reveal that the decrease in serum PON1 activity observed in non-dialyzed and dialyzed CKD patients as well as in renal transplant (RT) patients is linked to an increased vulnerability to atherosclerosis. We intend to summarize current literature concerning PON1 activity in CKD, highlighting on the main determinants of PON1 activity, its association with oxidative stress, the impact of its genetic polymorphism on the disease development, the effect of drugs and nutritional state. Furthermore, evidence supporting the implication of reduced PON1 activity in the incident of cardiovascular disease in CKD patients, is also examined. It appears that despite the lack of standardization of PON1 activity measurement, PON1 remains a valuable biomarker for the researchers through the last decades, which contributes to the assessment of the antioxidant status having prognostic benefit on adverse clinical outcomes at various stages and etiologies of kidney disease.
Published: 2024
Full Text: View/download PDF

34. Current therapeutic approach of chronic kidney disease-mineral and bone disorder.

Author: Zaimi M and Grapsa E
Subjects: Humans, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic therapy, Quality of Life, Chronic Kidney Disease-Mineral and Bone Disorder therapy, Chronic Kidney Disease-Mineral and Bone Disorder etiology
Abstract: Chronic kidney disease (CKD) has emerged as one of the leading noncommunicable diseases affecting >10% of the population worldwide. Bone and mineral disorders are a common complication among patients with CKD resulting in a poor life quality, high fracture risk, increased morbidity and cardiovascular mortality. According to Kidney Disease: Improving Global Outcomes, renal osteodystrophy refers to changes in bone morphology found in bone biopsy, whereas CKD-mineral and bone disorder (CKD-MBD) defines a complex of disturbances including biochemical and hormonal alterations, disorders of bone and mineral metabolism and extraskeletal calcification. As a result, the management of CKD-MBD should focus on the aforementioned parameters, including the treatment of hyperphosphatemia, hypocalcemia, abnormal PTH and vitamin D levels. Regarding the bone fragility fractures, osteoporosis and renal osteodystrophy, which constitute the bone component of CKD-MBD, anti-osteoporotic agents constitute the mainstay of treatment. However, a thorough elucidation of the CKD-MBD pathogenesis is crucial for the ideal personalized treatment approach. In this paper, we review the pathology and management of CKD-MBD based on the current literature with special attention to recent advances., (© 2024 The Author(s). Therapeutic Apheresis and Dialysis published by John Wiley & Sons Australia, Ltd on behalf of International Society for Apheresis and Japanese Society for Apheresis.)
Published: 2024
Full Text: View/download PDF

35. Placental and Renal Pathways Underlying Pre-Eclampsia.

Author: Andronikidi PE, Orovou E, Mavrigiannaki E, Athanasiadou V, Tzitiridou-Chatzopoulou M, Iatrakis G, and Grapsa E
Subjects: Pregnancy, Female, Humans, Placenta metabolism, Kidney metabolism, Pre-Eclampsia metabolism, Hypertension, Renal Insufficiency, Chronic complications
Abstract: Pre-eclampsia is a serious complication of pregnancy characterized by a state of multiorgan hypertensive disorders, with or without proteinuria and possible multiorgan dysfunction. Chronic kidney disease is an established risk factor for the development of pre-eclampsia, as angiogenic homeostasis is altered and the maternal circulation is already hypertensive. Facing pre-eclampsia in the context of chronic kidney disease is a challenging emergency for both the mother and the fetus. The clinical features and the management of this multi-organ disorder are clearly defined in the modern literature but the underlying pathophysiologic mechanisms remain not fully elucidated. Understanding the pathophysiology that mediates the onset of pre-eclampsia itself and in synergy with chronic kidney disease is fundamental for developing prompt prevention strategies, treatment planning, and patient counseling. This review aims to summarize the main molecular mechanisms involved in the process of pre-eclampsia, with a particular focus on the role of the kidneys and hormonal pathways related to renal function in normal pregnancy and pre-eclamptic syndromes.
Published: 2024
Full Text: View/download PDF

36. Perceptions of Teamwork and Knowledge Attitudes of Hemodialysis Unit Nurses on Infection Prevention.

Author: Prevyzi E, Patrinos S, Intas G, Elefsiniotis I, Velonakis E, and Grapsa E
Subjects: Humans, Child, Female, Cross-Sectional Studies, Health Knowledge, Attitudes, Practice, Attitude of Health Personnel, Surveys and Questionnaires, Renal Dialysis adverse effects, HIV Infections, Cross Infection prevention & control, Nurses
Abstract: Introduction: The Nurses of Hemodialysis Units: it is necessary to face HAIs (hospital-acquired infections) as a "well-tuned" teamwork. The aim of this study was to investigate the perceptions of the teamwork as well as the knowledge attitudes of the nurses of hemodialysis units on infection prevention in Greece., Methodology: A cross-sectional survey was conducted with a sample of 1018 HCWs (health care workers) of hemodialysis units in Greece. The questionnaires used were: Teamwork Perceptions Questionnaire (T-TPQ) TeamSTEPPS ® -Instructor Manual, and questionnaire APPENDIX A., Results: The majority of them were nurses (69.45%) and nurse assistants (23.87%). About teamwork perceptions per factor, we observed uniformity in their responses with very high rates of agreement. The attitudes of nurses of hemodialysis units on the prevention of infections were distinguished in particularly high rates of compliance with a high perception of the risk of transmission of infections with better compliance being that of women. Also, women seem to be more knowledgeable about diseases that mostly affect the pediatric population. It seemed that level of knowledge between the two sexes did not differ regarding HBV (63.16% vs. 66.71%, p = 0.430), HCV (63.91% vs. 66.71%, p = 0.553), HIV infection (78.95% vs. 81.76%, p = 0.471), and influenza (55.64% vs. 59.61%, p = 0.394)., Conclusions: This study highlighted for the first time the high level of perceptions of teamwork of the HCWs of the hemodialysis units in Greece. It is recommended to investigate the correct application of prevention measures and to detect the causes of deviation from good practices with subsequent investigations on hemodialysis units of Greece., (© 2023. The Author(s), under exclusive license to Springer Nature Switzerland AG.)
Published: 2023
Full Text: View/download PDF

37. The Role of Heme Oxygenase-1 as an Immunomodulator in Kidney Disease.

Author: Athanassiadou V, Plavoukou S, Grapsa E, and Detsika MG
Abstract: The protein heme oxygenase (HO)-1 has been implicated in the regulations of multiple immunological processes. It is well known that kidney injury is affected by immune mechanisms and that various kidney-disease forms may be a result of autoimmune disease. The current study describes in detail the role of HO-1 in kidney disease and provides the most recent observations of the effect of HO-1 on immune pathways and responses both in animal models of immune-mediated disease forms and in patient studies.
Published: 2022
Full Text: View/download PDF

38. Association Between Vaccination Status and Mortality Among Intubated Patients With COVID-19-Related Acute Respiratory Distress Syndrome.

Author: Grapsa E, Adamos G, Andrianopoulos I, Tsolaki V, Giannakoulis VG, Karavidas N, Giannopoulou V, Sarri K, Mizi E, Gavrielatou E, Papathanakos G, Mantzarlis KD, Mastora Z, Magira E, Koulouras V, Kotanidou A, and Siempos II
Subjects: Adult, Aged, BNT162 Vaccine, COVID-19 Vaccines, ChAdOx1 nCoV-19, Cohort Studies, Humans, Male, SARS-CoV-2, United States epidemiology, Vaccination, COVID-19 complications, Respiratory Distress Syndrome therapy
Abstract: Importance: Although vaccination substantially reduces the risk of severe COVID-19, it is yet unknown whether vaccinated patients who develop COVID-19 and require invasive mechanical ventilation have lower mortality than controls., Objective: To examine the association between COVID-19 vaccination status and mortality among critically ill patients who require invasive mechanical ventilation owing to acute respiratory distress syndrome (ARDS) related to COVID-19., Design, Setting, and Participants: This multicenter cohort study was performed between June 7, 2021, and February 1, 2022, among 265 consecutive adult patients with COVID-19 in academic intensive care units who underwent invasive mechanical ventilation owing to ARDS., Exposures: Patients in the full vaccination group had completed the primary COVID-19 vaccination series more than 14 days but less than 5 months prior to intubation. This time threshold was chosen because guidelines from the US Centers for Disease Control and Prevention recommend a booster dose beyond that time. The remaining patients (ie, those who were unvaccinated, partially vaccinated, or fully vaccinated <14 days or >5 months before intubation) comprised the control group., Main Outcomes and Measures: The primary outcome was time from intubation to all-cause intensive care unit mortality. A Cox proportional hazards regression model including vaccination status, age, comorbid conditions, and baseline Sequential Organ Failure Assessment score on the day of intubation was used., Results: A total of 265 intubated patients (170 men [64.2%]; median age, 66.0 years [IQR, 58.0-76.0 years]; 26 [9.8%] in the full vaccination group) were included in the study. A total of 20 patients (76.9%) in the full vaccination group received the BNT162b2 vaccine, and the remaining 6 (23.1%) received the ChAdOx1 nCoV-19 vaccine. Patients in the full vaccination group were older (median age, 72.5 years [IQR, 62.8-80.0 years] vs 66.0 years [IQR, 57.0-75.0 years]) and more likely to have comorbid conditions (24 of 26 [92.3%] vs 160 of 239 [66.9%]), including malignant neoplasm (6 of 26 [23.1%] vs 18 of 239 [7.5%]), than those in the control group. Full vaccination status was significantly associated with lower mortality compared with controls (16 of 26 patients [61.5%] died in the full vaccination group vs 163 of 239 [68.2%] in the control group; hazard ratio, 0.55 [95% CI, 0.32-0.94]; P = .03)., Conclusions and Relevance: In this cohort study, full vaccination status was associated with lower mortality compared with controls, which suggests that vaccination might be beneficial even among patients who were intubated owing to COVID-19-related ARDS. These results may inform discussions with families about prognosis.
Published: 2022
Full Text: View/download PDF

39. Prognostic and Diagnostic Value of Endocan in Kidney Diseases.

Author: Samouilidou E, Athanasiadou V, and Grapsa E
Abstract: Endocan, previously called endothelial cell-specific molecule-1, is a soluble proteoglycan that is predominantly expressed in vascular endothelial cells of the lungs and kidneys. It is upregulated by proinflammatory cytokines and plays a critical role in inflammatory, proliferative, and neovascularization processes. The utility of endocan as a biomarker in a wide spectrum of diseases is being increasingly acknowledged. In this review, we summarize the current evidence concerning the role of endocan in kidney diseases, with emphasis on its prognostic and diagnostic value. It seems that the determination of plasma endocan levels may provide useful prognostic information in many types of renal failure such as chronic kidney disease, IgA nephropathy, and diabetic nephropathy. Endocan could additionally improve the early diagnostic evaluation of acute kidney disease, chronic renal allograft injury, and acute rejection after kidney transplantation, thus contributing to endothelial cell injury monitoring in a timely manner., Competing Interests: The authors have no conflicts of interest to declare., (Copyright © 2022 Elisabeth Samouilidou et al.)
Published: 2022
Full Text: View/download PDF

40. Evaluation of Pupils' Knowledge about Kidney Health.

Author: Vassilikopoulos T, Kalokairinou A, Kourlaba G, and Grapsa E
Subjects: Child, Cross-Sectional Studies, Female, Greece, Humans, Male, Kidney physiology, Schools
Abstract: The purpose of this study was to investigate the level of renal function knowledge of primary school pupils in Greece. We conducted a cross-sectional study with a convenience sample of 220 pupils, coming from the 5th and 6th grades of general education schools. A questionnaire consisting of 11 questions was developed from scratch. However, based on an analysis of Cronbach's alpha values obtained when individual questions were deleted, two questions were removed from the analysis, and only nine remained for analysis and participated in the calculation of the knowledge score. Moreover, the gender and daily habits of pupils regarding water consumption and frequency of urination were recorded. Pupils had a high percentage of correct knowledge about the number of kidneys (95.2%), whether a child may have problems with the kidneys (85.5%) and whether a person can survive with one kidney (68.5%). Low levels of knowledge were observed in the function and role of the kidneys (36.4%), as well as the part of the body where the kidneys are located (30.9%). The median (interquartile range (IQR)) total knowledge score was 6 (5-7), with no difference detected between genders ( p = 0.135). A statistically significant difference between pupils of 5th and 6th grades was found but the difference did not seem to be clinically significant ( p = 0.035). The present research demonstrates that pupils' knowledge of renal function and the protection of their kidneys needs improvement.
Published: 2021
Full Text: View/download PDF

41. Lipoprotein apheresis: a Hellenic consensus on its clinical use.

Author: Kolovou G, Kolovou V, Bilianou H, Goumas G, Foussas S, Grapsa E, Garoufi A, Karavolias G, Mavrogieni S, Melidonis A, Milionis H, Rallidis L, Richter D, Skoumas I, Tousoulis D, Vlachopoulos C, and Liberopoulos E
Subjects: Biomarkers, Consensus, Humans, Lipoproteins, Treatment Outcome, Blood Component Removal
Abstract: Competing Interests: Declaration of interest GK: participated in research and consulting activities sponsored by healthcare companies, including Amgen, MSD, Sanofi, and Servier; GG: VK: has participated in research studies sponsored by Amgen, Sanofi, and Regeneron; AM: participated in educational, research, and consulting activities sponsored by healthcare companies, including Lybitec, Lilly, Boehringer, Demo, Novo, Glaxo, Astra, and Amgen; HM: participated in educational, research and consulting activities sponsored by healthcare companies, including Amgen, Bayer, Mylan, MSD, Pfizer, Sanofi, and Servier; LR has received research grants, honoraria, and travel grants from Amgen, MSD, ELPEN, Sanofi, Mylan and Servier; DR: has participated in educational, research, and advisory activities sponsored by AstraZeneca, MSD, Lilly, Bayer, Amgen, Sanofi, Boehringer-Ingelheim, Elpen, Mylan, Unipharma, Lavipharm, and Servier; IS: has received research grants and honoraria from Amgen, Sanofi, MSD, and Elpen. LR has received honoraria for lectures, clinical trials, and consultant fees from Amgen, MSD, MYLAN, Servier, AstraZeneca, and Sanofi-Aventis; DT: participated in research and consulting activities sponsored by healthcare companies, including Amgen, MSD, Sanofi, Servier, Pfizer, and Boehringer-Ingelheim; CV has received research grant(s)/support and honoraria from Amgen, MSD, ELPEN, Sanofi, VIANEX; EL: has participated in educational, research, and advisory activities sponsored by AstraZeneca, MSD, Lilly, Bayer, Amgen, Sanofi, Boehringer-Ingelheim, Novartis, Novo Nordisk, and Servier; HB, SF, AG, EG, GK, SM: No conflict of interest to declare.
Published: 2021
Full Text: View/download PDF

42. Generation of a novel decay accelerating factor (DAF) knock-out rat model using clustered regularly-interspaced short palindromic repeats, (CRISPR)/associated protein 9 (Cas9), genome editing.

Author: Detsika MG, Goudevenou K, Geurts AM, Gakiopoulou H, Grapsa E, and Lianos EA
Subjects: Acute Kidney Injury pathology, Albuminuria, Animals, Antibodies, Anti-Idiotypic pharmacology, CD55 Antigens deficiency, CD55 Antigens immunology, CRISPR-Cas Systems genetics, Complement Activation immunology, Complement C3-C5 Convertases genetics, Complement C5 genetics, Gene Knockout Techniques, Heymann Nephritis Antigenic Complex genetics, Heymann Nephritis Antigenic Complex immunology, Humans, Podocytes pathology, Rats, Acute Kidney Injury genetics, CD55 Antigens genetics, Complement Activation genetics, Podocytes metabolism
Abstract: Decay accelerating factor (DAF), a key complement activation control protein, is a 70 kDa membrane bound glycoprotein which controls extent of formation of the C3 and C5 convertases by accelerating their decay. Using clustered regularly-interspaced short palindromic repeats, (CRISPR)/associated protein 9 (Cas9) genome editing we generated a novel DAF deficient (Daf -/- ) rat model. The present study describes the renal and extrarenal phenotype of this model and assesses renal response to complement-dependent injury induced by administration of a complement-fixing antibody (anti-Fx1A) against the glomerular epithelial cell (podocyte). Rats generated were healthy, viable and able to reproduce normally. Complete absence of DAF was documented in renal as well as extra-renal tissues at both protein and mRNA level compared to Daf +/+ rats. Renal histology in Daf -/- rats showed no differences regarding glomerular or tubulointerstitial pathology compared to Daf +/+ rats. Moreover, there was no difference in urine protein excretion (ratio of urine albumin to creatinine) or in serum creatinine and urea levels. In Daf -/- rats, proteinuria was significantly increased following binding of anti-Fx1A antibody to podocytes while increased C3b deposition was observed. The DAF knock-out rat model developed validates the role of this complement cascade regulator in immune-mediated podocyte injury. Given the increasing role of dysregulated complement activation in various forms of kidney disease and the fact that the rat is the preferred animal for renal pathophysiology studies, the rat DAF deficient model may serve as a useful tool to study the role of this complement activation regulator in complement-dependent forms of kidney injury.
Published: 2021
Full Text: View/download PDF

43. Primary adrenal leiomyosarcoma: A case report.

Author: Sakellariou M, Dellaportas D, Grapsa E, Tzikanoulas M, Dellis A, Theodosopoulos T, and Nastos C
Abstract: Adrenal leiomyosarcomas are rare mesenchymal tumors of the suprarenal region that are usually diagnosed after they have reached a large size. We report the case of a 62-year-old male with an incidentally found left adrenal mass. Magnetic resonance imaging of the retroperitoneal space showed a heterogeneously enhanced mass, measuring 10x8.2 cm, with characteristics suspicious of malignancy. The patient underwent left radical adrenalectomy after the hormonal evaluation of the tumor due to the high probability of adrenocortical carcinoma. However, microscopic examination of the tumor showed a spindle cell sarcoma. Immunohistochemically the neoplastic cells were found positive for desmin and smooth muscle actin and the diagnosis of a well differentiated adrenal leiomyosarcoma was established. During follow-up the patient presented an aggressive course as he developed bone, liver and pulmonary metastases early postoperatively, which were treated with radiation therapy and chemotherapy. The patient has progressive metastatic disease while on chemotherapy 31 months after surgery., (Copyright © 2019, Spandidos Publications.)
Published: 2020
Full Text: View/download PDF

44. Immunosuppressive regimens based on Cyclophospamide or Calcineurin inhibitors: Comparison of their effect in the long term outcome of Primary Membranous Nephropathy.

Author: Stangou M, Marinaki S, Papachristou E, Kolovou K, Sambani E, Zerbala S, Papadea P, Balafa O, Rapsomanikis KP, Andrikos A, Manolakaki P, Papadopoulou D, Mitsopoulos E, Liakou H, Andronikidi PE, Choulitoudi V, Moustakas G, Galitsiou D, Dafnis E, Stylianou K, Stefanidis I, Golfinopoulos S, Panagoutsos S, Tsilivigkou M, Papadogianakis A, Tzanakis I, Sioulis A, Vlachakos D, Grapsa E, Spaia S, Kaperonis N, Paliouras C, Dioudis C, Papoulidou F, Apostolou T, Iatrou C, Boletis I, Goumenos D, and Papagianni A
Subjects: Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Young Adult, Calcineurin Inhibitors therapeutic use, Cyclophosphamide therapeutic use, Glomerulonephritis, Membranous drug therapy, Immunosuppressive Agents therapeutic use
Abstract: Introduction: Management of the Primary Membranous Nephropathy (PMN) usually involves administration of immunosuppressives. Cyclophosphamide (Cyclo) and Calcineurin Inhibitors (CNIs) are both widely used but only limited data exist to compare their efficacy in long term follow-up., Aim: The aim of the present study was to estimate and compare long term effects of Cyclo and CNIs in patients with PMN., Patients-Methods: Clinical data, histologic findings and long term outcome were retrospectively studied. The response to treatment and rate of relapse was compared between patients treated with CNIs or Cyclo based immunosuppressive regimens., Results: Twenty three centers participated in the study, with 752 PMN patients (Mean age 53.4(14-87) yrs, M/F 467/285), followed for 10.1±5.7 years. All patients were initially treated with Renin Angiotensin Aldosterone System inhibitors (RAASi) for at least 6 months. Based on their response and tolerance to initial treatment, patients were divided into 3 groups, group I with spontaneous remission, who had no further treatment, group II, continued on RAASi only, and group III on RAASi+immunosuppression. Immunosuppressive regimes were mainly based on CNIs or Cyclo. Frequent relapses and failure to treatment were more common between patients who had started on CNIs (n = 381) compared to those initially treated with Cyclo (n = 110), relapse rate: 25.2% vs. 6.4%, p<0.0001, and no response rate: 22.5% vs. 13.6%, p = 0.04, respectively., Conclusions: Long term follow up showed that administration of Cyclo in PMN is followed by better preservation of renal function, increased response rate and less frequent relapses, compared to CNIs., Competing Interests: The authors have declared that no competing interests exist.
Published: 2019
Full Text: View/download PDF

45. Swift Cure of a Chronic Wound Infected With Multiresistant Staphylococcus aureus in an Elderly Patient With Stage 5 Renal Disease.

Author: Kyriakopoulos AM, Grapsa E, Marcinkiewicz J, and Nagl M
Subjects: Administration, Topical, Aged, 80 and over, Anti-Inflammatory Agents administration & dosage, Chronic Disease, Drug Resistance, Microbial, Drug Resistance, Multiple, Drug Therapy, Combination, Female, Humans, Kidney Failure, Chronic diagnosis, Lower Extremity, Prognosis, Risk Assessment, Staphylococcal Infections complications, Staphylococcal Infections diagnosis, Taurine administration & dosage, Taurine analogs & derivatives, Wound Healing physiology, Wound Infection complications, Anti-Infective Agents therapeutic use, Kidney Failure, Chronic complications, Staphylococcal Infections drug therapy, Wound Healing drug effects, Wound Infection drug therapy, Wound Infection microbiology
Abstract: We present a case of a 91-year-old female with stage 5 renal disease, diabetes type 2, and considerable weakness, suffering from a 2-month-old wound infected by a multiresistant Staphylococcus aureus . The wound measured 7 cm in length, 5 cm in width, and 1.5 cm in depth, having purulent white edges and exudates exceeding the size of the wound. The systemic antibiotic use was opposing to improve the patient's clinical condition due to underlying nephrotoxicity that may have deteriorated renal failure and resistance of the infecting pathogen. The halogenated taurine (Tau) derivatives N-chlorotaurine (NCT) and N-bromotaurine (NBrT) with potent anti-inflammatory and antimicrobial efficacy were alternatively employed as combination topical treatment to provide a therapeutic solution. Each agent was applied separately with an interval of 5 minutes as a 1% spray in aqueous solution every 30 minutes during the day for 3 days. This treatment was very well tolerated and led to rapid disappearance of the purulent exudate, rapid epithelialization, and complete healing. To avoid relapse, the application was continued 4 times daily for a further 4 days. No complications occurred in the course of treatment. This case report confirms the therapeutic efficacy of NCT in chronic purulent wounds. NBrT is well tolerated, too, and can be used in combination with NCT in emergency clinical settings. Its potential as a single agent should be investigated in further studies. Advancement of wound closure by these agents proved to be life-saving for this patient. Further molecular research is needed to identify mechanisms that promote wound healing.
Published: 2019
Full Text: View/download PDF

46. Anxiety-Depression of Dialysis Patients and Their Caregivers.

Author: Gerogianni G, Polikandrioti M, Babatsikou F, Zyga S, Alikari V, Vasilopoulos G, Gerogianni S, and Grapsa E
Subjects: Aged, Anxiety epidemiology, Caregivers statistics & numerical data, Cross-Sectional Studies, Depression epidemiology, Dialysis methods, Dialysis statistics & numerical data, Female, Greece, Humans, Logistic Models, Male, Middle Aged, Psychometrics instrumentation, Psychometrics methods, Surveys and Questionnaires, Anxiety diagnosis, Caregivers psychology, Depression diagnosis
Abstract: Background and Objectives : Anxiety-depression of patients undergoing hemodialysis has a strong relation with the levels of anxiety-depression of their caregivers. The aim of this study was to evaluate anxiety-depression of dialysis patients and their caregivers. Materials and Methods : In this cross-sectional study, 414 pairs of patients and caregivers from 24 hemodialysis centers of Greece completed the Hospital Anxiety and Depression Scale (HADS). The statistical analysis of the data was performed through the Statistical Program SPSS version 20.0. The statistical significance level was set up at 5%. Results : The mean age of patients was 64 (54.06-72.41) years old and the mean duration of hemodialysis was 36 (16-72) months. The mean age of caregivers was 54 (44-66) years old. Of the total sample, 17.1% ( n = 71) of patients had high levels of anxiety and 12.3% ( n = 51) had high levels of depression. Additionally, 27.8% ( n = 115) of caregivers had high levels of anxiety and 11.4% ( n = 47) had high levels of depression. Caregivers had higher levels of anxiety when their patients had high levels of anxiety as well (42.3%). Additionally, they had higher levels of depression when their patients had high levels of depression as well (17.6%). Conclusions : The results of this study showed a significant association between the levels of anxiety and depression among patients and caregivers. There is a necessity for individualized assessment of dialysis patients and their caregivers and the implementation of specific interventions for reducing the levels of anxiety and depression among them., Competing Interests: The authors declare that they have no conflict of interest.
Published: 2019
Full Text: View/download PDF

47. Management of anxiety and depression in haemodialysis patients: the role of non-pharmacological methods.

Author: Gerogianni G, Babatsikou F, Polikandrioti M, and Grapsa E
Subjects: Humans, Psychosocial Support Systems, Quality of Life, Renal Dialysis methods, Acupressure methods, Anxiety physiopathology, Anxiety therapy, Cognitive Behavioral Therapy methods, Depression physiopathology, Depression therapy, Kidney Failure, Chronic psychology, Kidney Failure, Chronic therapy, Relaxation Therapy methods, Renal Dialysis psychology
Abstract: Anxiety and depression in patients undergoing haemodialysis can be reduced by a variety of treatment methods, including pharmacological therapy, cognitive-behavioural therapy, regular exercise and relaxation techniques, such as Benson's relaxation method and acupressure treatment. Additionally, intradialytic exercise training programmes have a positive effect on patients' physical and psychological functioning. Moreover, social support from family and social environment, spirituality and religiosity, tele- nursing programmes and participation in network support groups frequently lead to a reduction of anxiety and depressive symptoms in these people. Finally, the provision of education and information to dialysis patients by renal professionals and a systematic psychiatric evaluation of these individuals can lead to early diagnosis and treatment of depressive symptoms.
Published: 2019
Full Text: View/download PDF

48. Serum Endocan Levels are Associated With Paraoxonase 1 Concentration in Patients With Chronic Kidney Disease.

Author: Samouilidou E, Bountou E, Papandroulaki F, Papamanolis M, Papakostas D, and Grapsa E
Subjects: Adult, Aged, Aged, 80 and over, Atherosclerosis pathology, Case-Control Studies, Female, Humans, Inflammation pathology, Lipids blood, Male, Middle Aged, Regression Analysis, Renal Dialysis methods, Renal Insufficiency, Chronic physiopathology, Renal Insufficiency, Chronic therapy, Young Adult, Aryldialkylphosphatase blood, Dyslipidemias blood, Neoplasm Proteins blood, Proteoglycans blood, Renal Insufficiency, Chronic blood
Abstract: Endocan is a soluble proteoglycan released by the vascular endothelium. The increase of its serum levels is associated with inflammation, endothelial dysfunction and cardiovascular events in patients with chronic kidney disease (CKD). We studied the association of serum endocan with the lipid profile of 105 CKD patients with dyslipidemia, divided in two groups, non-dialyzed (CKD, N = 57) and hemodialysis (HD, N = 48) in comparison with 30 normal controls (NC). We also analyzed endocan in relation with the concentration of two serum HDL-linked members of the paraoxonase (PON) family, PON1 and PON3, which have been previously found to have antiatherogenic properties. The results showed that endocan levels were significantly higher in HD patients than in CKD patients (P < 0.001) and NC (P < 0.001). PON1 was significantly decreased only in HD patients compared to NC (P < 0.001), whereas PON3 was significantly increased in both patient groups (P < 0.001). Endocan levels were significantly and positively correlated with total cholesterol and LDL-C in CKD and additionally were negatively correlated with HDL-C in HD group. PON1 levels were significantly correlated with endocan in both groups, while no correlation was observed for PON3 in either group. Multiple regression analysis between endocan and the above lipid parameters in the total of patients revealed that endocan was independently associated only with PON1 (β = -0.513, P = 0.002). It is concluded that the increase of serum endocan levels in patients with CKD may be associated with the decrease of PON1 concentration, irrespective of lipid alterations produced by atherosclerosis development., (© 2018 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.)
Published: 2018
Full Text: View/download PDF

49. A holistic approach to factors affecting depression in haemodialysis patients.

Author: Gerogianni G, Kouzoupis A, and Grapsa E
Subjects: Global Health, Humans, Morbidity trends, Depression epidemiology, Depression etiology, Depression psychology, Kidney Failure, Chronic therapy, Quality of Life, Renal Dialysis psychology
Abstract: Depression in dialysis populations is affected by co-morbid diseases, such as cardiovascular disease, diabetes, and immune dysfunction, and it also includes high suicide risk and frequent hospitalizations. Depressive disorders have a close association with malnutrition and chronic inflammation, as well as with cognitive impairment. Impaired cognitive function may be manifested as low adherence to dialysis treatment, leading to malnutrition. Additionally, chronic pain and low quality of sleep lead to high rates of depressive symptoms in haemodialysis patients, while an untreated depression can cause sleep disturbances and increased mortality risk. Depression can also lead to sexual dysfunction and non-adherence, while unemployment can cause depressive disorders, due to patients' feelings of being a financial burden on their family. The present review provides a holistic approach to the factors affecting depression in haemodialysis, offering significant knowledge to renal professionals.
Published: 2018
Full Text: View/download PDF

50. The role of socio-demographic factors in depression and anxiety of patients on hemodialysis: an observational cross-sectional study.

Author: Gerogianni G, Lianos E, Kouzoupis A, Polikandrioti M, and Grapsa E
Subjects: Age Factors, Aged, Comorbidity, Cross-Sectional Studies, Educational Status, Female, Greece epidemiology, Humans, Income, Male, Marital Status, Middle Aged, Prevalence, Psychiatric Status Rating Scales, Retirement psychology, Sex Factors, Anxiety epidemiology, Depression epidemiology, Renal Dialysis psychology
Abstract: Purpose: Depression and anxiety have high prevalence in patients on hemodialysis and are strongly associated with socio-economic factors. The aim of this study was to evaluate the prevalence of depression and anxiety in hemodialyzed patients in Greece and its association with socio-demographic factors., Methods: Four hundred and fourteen (414) patients on hemodialysis (262 males and 152 females) from 24 dialysis centers in Greece participated in this observational cross-sectional study. Mean age was 63.54 (54.06-72.41), and mean time of dialysis treatment was 36 (16-72) months. Depression and anxiety were assessed by the state-trait anxiety inventory (STAI), the beck depression inventory (BDI) and the hospital anxiety and depression scale (HADS). Multinomial logistic regression was performed to estimate the factors being independently associated with anxiety and depression levels (HADS scale). Multiple linear regression was performed to estimate the factors being independently associated with BDI and STAI., Results: From a total of 414 participants, (29.4%, n = 122) had depression and 35.9% (n = 149) had anxiety. Depression and anxiety were significantly associated with females, low level of education, increased patients' age, retirement, poor financial situation, marital status and co-morbidities., Conclusion: The overall study findings indicated a significant correlation between the levels of anxiety and depression in patients on hemodialysis. Patients with high levels of anxiety had higher levels of depression and those with high depression scores had higher anxiety scores.
Published: 2018
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

101 results on '"E. Grapsa"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources